KLT对中脑神经系统疾病的影响及KLT、NDV、SW联合抗肿瘤作用机制研究
摘要
目前癌症已经跃为威胁人类健康的第一杀手,治疗或消灭肿瘤成为世界医学界的难题,治疗神经系统肿瘤和疾病,诸如中脑神经母细胞瘤、帕金森氏病等成为当前最为迫切解决的热门课题之一。神经系统肿瘤疾病的治疗对于提高人类生活质量、延长人类寿命至关重要。人们应用手术、化疗、中药治疗、基因治疗、自身免疫治疗等手段虽然有一定治疗效果,但是伴随的毒副作用和昂贵的治疗费使患者倍受痛苦,甚至放弃治疗。有效地无毒副作用治疗肿瘤疾病是研究者多年的追求和愿望。因而,探索生物学因素中药康莱特(KLT)对中脑神经组织的影响,探索KLT、溶瘤病毒新城疫病毒(NDV)和豆类丝核菌代谢产物苦马豆素(SW)联合抗肿瘤疾病的作用机制是本研究的选题目的。
本研究通过建立的S37动物肿瘤模型,运用H.E染色、TH染色、NeuN染色、GFAP染色技术和免疫组化SP法研究了三种药物抗肿瘤的效果及其作用机制。
本研究取得以下结果:
1.成功地对中脑神经组织进行了体外培养。试验表明,用1-4d胚鼠中脑组织培养运用基础培养基;5-10d,置换为N4培养基,初级突起和次级突起得到了充分的发育,并由突起形成了网络状结构。
2.将KLT作用于中脑组织培养,表明添加不同浓度KLT作用后,浓度为0.001mg/ml的KLT对多巴胺能神经元具有促进生长的作用,神经元数量增加了13.3%,浓度为0.01mg/ml、0.1mg/ml、1.0mg/ml的KLT作用后,神经元的数量有所下降,表明高浓度KLT对中脑组织有轻微毒害作用,低浓度KLT能够很好地刺激中脑组织神经元的生长。
3.用KLT作用于帕金森症模型中,用不同浓度KLT作用于受损的多巴胺能神经元,结果表明,各浓度KLT稀释液均能显著提升多巴胺能神经元神经元的数量,浓度为0.001mg/ml的KLT比对照度提高了88%。且细胞突起明显变长,次级突起数量增多,胞体圆滑。
4.N18TG2神经母细胞瘤在N4培养基中呈现旺盛生长,胞体变大,伸出几个大的初级突起,初级突起上伸出很多细丝状的次级突起。MTT结果表明在12h,24h和48h,在N4培养基中N18TG2生长速度显著高于NBT培养基中的生长速度,在48h时,N4培养基中的细胞数是NBT培养基中的3倍。
5.实现了胚鼠中脑组织与鼠源神经母细胞瘤N18TG2的共培养。将接种浓度为2.5×104、5.0×104和105 cells/ml的N18TG2神经母细胞瘤细胞接种于中脑神经组织。结果显示,各接种浓度均能在中脑组织中生长,但生长比较缓慢。N18TG2低接种浓度共培养中,神经母细胞瘤对中脑组织细胞几乎无伤害作用,只有高浓度接种的肿瘤细胞才对神经元形成毒害作用,神经元出现胞突变短,胞体肿胀,次级突起消失;神经元数量减少等变化。
6.不同浓度KLT作用于N4培养基和NBT培养基的神经母细胞瘤N18TG2, MTT结果显示,各浓度KLT均对N18TG2神经母细胞瘤的有极显著的抗肿瘤效果。高浓度KLT组中可见到大量的肿瘤细胞碎片,在各种浓度KLT上清液中均能见到大量凋亡小泡,表明KLT对N18TG2神经母细胞瘤的抗肿瘤作用呈现剂量依赖关系,高浓度KLT导致肿瘤细胞发生坏死,低浓度KLT诱导肿瘤细胞凋亡。
7.不同浓度KLT作用于神经母细胞瘤N18TG2细胞与中脑组织共培养中,结果显示,浓度为0.001mg/ml的KLT的肿瘤细胞数在各个时期均显著低于对照组,肿瘤抑制率为36%,且该组神经元的初级突起和次级突起均是完整的,神经元突起构成的网络结构依然清晰。在其他浓度KLT作用下,肿瘤细胞有所减少,但差异不显著。同时在共培养组织中也见到大量呈圆形无突起的神经元细胞,表明在共培养组织中低浓度组KLT具有抑制肿瘤细胞的效果。
8.不同浓度KLT作用于神经母细胞瘤N18TG2细胞与中脑组织共培养中,结果表明,KLT各作用组对多巴胺能神经元、神经元和神经胶质细胞的数量大大增加,且细胞胞体和突起较平滑,突起数目较多,较长,神经元突起构成的网络较清晰。表明KLT能很好地保护中神经细胞。
9.建立了S37肿瘤模型鼠,将48只S37荷瘤小鼠随机分成4组,即对照组、NDV治疗组、康莱特治疗组和NDV联合康莱特治疗组。体内抗肿瘤效果表明,随时间延长,肿瘤组织生长缓慢、肿瘤细胞发生溶解、核固缩、坏死区可见到大量的淋巴细胞,三种药物具有显著地抗肿瘤作用,其中NDV弱毒和康莱特注射液联用组的抗肿瘤效果最好,康莱特组次之,NDV组稍差。其抗肿瘤作用机制有可能是三种药物提高了机体神经系统和免疫系统机能,破坏或减弱了瘤细胞的生长繁殖速度,引起瘤细胞凋亡和死亡,起到了抗肿瘤作用。
10.建立了S37肿瘤模型鼠,将48只S37荷瘤小鼠随机分成4组,即NDV治疗组、苦马豆素组治疗组、NDV联合苦马豆素治疗组和对照组。体内试验结果表明结果表明,随时间延长,肿瘤组织坏死严重、肿瘤细胞发生溶解、核固缩、坏死区可见到大量的淋巴细胞,三种药物具有显著地抗肿瘤作用,其中NDV弱毒和SW联用组的抗肿瘤效果最好,NDV组次之,SW组稍差。其抗肿瘤机制可能与三种药物均能刺激并提高机体免疫系统和神经系统机能,抑制或直接杀伤了肿瘤细胞,诱导肿瘤细胞凋亡或坏死,起到了抗肿瘤作用。
Cancers are the first killer for threatening human healthes. Curing or cancelling tumors is a big problem on the world. While how to cure midbrain system disease and tumors in midbrain such as neuroblastoma and Parkinesons have become as the hottest projects to attack. It’s very important to attack nerve system tumor for leveling up the quality of the sick and extend human life. The operations, chemo-treatment, treatment by Chinese herbs, gene therapy, immunization theropy are used on the patients. Though have some effects but the toxic side effect and expensive curing fees can’t be bearable by the patients and their families. Some patients even give up treatments. To find no toxic side effects and effective new ways for curing cancer is most researchers’wishes. So to study biology factors Chinese herb Kanglaite injection (KLT) influence on the midbrain tissue. Then to study the mechanism of antitumor cooperation of Oncolytic virus New castle disease virus (NDV), KLT and secondary metabolite of Rhizoctonia leguminicola swaisonie (SW). Both researches are what our project want to do.
This research we built S37 models,, H.E staining TH staining,NeuN staining and GFAP staining technical were used in our study for getting more antitumor mechanism informations from threemedicines. The results as follows:
1. The midbrain cultures were successfully built from 14-day old mouse embryos. From 1-5 day the midbrain cultures were maintained in the basic medium and the cell bodies grew bigger and bigger. There are some short processes appeared. From 5-10 days, the midbrain culture medium was changed by N4 medium. Many long processes were sprayed out from the cell bodies and the second processes can be found. And the processes were formed very big network in the cultures. All these mean that midbrain tissue could be grown well outside body.
2. It’s the first time that KLT were used in the midbrain cultures to detect if there is some cytotoxixity on the midbrain cultures. The different dilutions of KLT were added. The results showed that the concentration of 0.001mg/ml could stimulate neurons growing faster and the number of the neurons increased 13.3%. While the number of the neurons in other KLT solutions had some little decrease. All means that higher concentrations of KLT do some harms to midbrain cultures. However the lower concentrations could well stimulate the growth of the neurons.
3. The 200μM MPP+ were used to build Parkinsonismus mould. Different concentrations of KLT were used to do some treatments on the hurted dopaminergic neurons. The numbers of the dopaminergic neurons were counted and statistics and the morphology changes can be seen on the dopaminergic neurons. The concentration of 0.001mg/ml leveled up the number of the dopaminergic neurons 88% in contrast to the control. And the processes of the dopaminergic neurons became more longer and the neutrites possess more to the control. The results showed that KLT could be used to cure the Parkinsonismus.
4. The N18TG2 neuroblastoma cells was the first time to grow in the midbrain culture medium N4 medium to detect if the N18TG2 can be growed in the N4 medium. The morphology changes and MTT assay showed that the N18TG2 can grow very well inside the N4 medium. Many big primary processes showed up and many second processes on the primary. The bodies of the N18TG2 become more bigger and bigger. MTT results suggested that the N18TG2 cells grew more quickly than the N18TG2 inside NBT medium in 12h,24h and 48h. Especially the number of N18TG2 cell in N4 medium is triple to the NBT medium. So the N18TG2 cells can grow in the midbrain medium.
5. It’s the first time that N18TG2 neuroblastoma cells were cocultured with midbrain tissue. The seeding densities of the N18TG2 cells are 2.5×104,5.0×104 and 105 cells/ml and were seeded in the midbrain culture. Take pictures at 12h,24h,36h and 48h separately. The numbers of the tumor cells were counted and statistics and the morphology changes could be found. The results showed that the N18TG2 could grow in the midbrain culture in all seeding densities but grew very slowly. Lower seeding densities N18TG2 cells can’t do cytotoxicity on neurons in midbrain culture. While higher seeding densities made the neuron swell and the processes became shorter and the second processes disappeared. The number of the neurons was decreased.
6. To detect the antitumor effects of KLT on N18TG2 neuroblastoma in N4 medium and NBT medium. The different concentrations of KLT treatments on N18TG2 neuroblastoma were added. The antitumor effect values were detected by MTT assay. The results showed that the KLT treatments have significant antitumor effects contrast to the control either in N4 medium or in NBT medium. Plenty of fragments and many apoptotic vesicles can be found in the culture suspension especially in the higher KLT concentrations. The results suggest that KLT treatments on N18TG2 neuroblastoma are dose dependent on the antitumor effects. And higher KLT solutions can make cancer cells depressed and lower KLT solutions induce apoptosis on N18TG2 neuroblastoma. The inhibition rate of 1.0mg/ml KLT is 48.7%.
7. KLT was used in the coculture for studying the antitumor effects on the N18TG2 neuroblastoma cells. The different KLT solutions were added into the coculture separately for another 48h. The numbers of the tumor cells were counted and statistics and the morphology changes could be found. The results showed that 0.001mg/ml KLT solution possessed significant lowest tumor number in all the tests in different periods to the control. The inhibition rate is 36%. The morphology showed that the primary processes and second processes didn’t been hurted and the networks made by processes were very clear. In other KLT solution treatment, the number of the tumor cells was decreased but not significantly to the control. Many round, no processes neuron could be found in other KLT solutions. These suggest that 0.001mg/ml KLT solution possess antitumor effect in the coculture of midbrain neurons and N18TG2 neuroblastoma.
8.After different solutions of KLT treatments on the coculture of neuroblastoma cells and midbrain cells, the numbers of the dopaminergic neurons, all neurons and astrocytes were counted and statistics and the morphology changes could be found. The morphology showed that the primary processes and second processes didn’t been hurted and the networks made by processes were very clear. The numbers of the dopaminergic neurons, all neurons and astrocytes were increased quickly and the bodies and the processes are very smooth. The decrease of the dopaminergic neurons, all neurons and astrocytes in the control was easy to find. Many apoptotic vesicle can be found in the bodies and the processes. KLT could level up the numbers of the dopaminergic neurons, all neurons and astrocytes and improve the lives of the neurons.
9 After building the cancer models, 48 cancer models were divided into three groups. Those are control group, Kanglaite injection group and NDV+Kanglaite group. The results suggested that the tumors grew very slowly, the tumor cells were dissolved and karyopyknosis when time expand. Plenty of lymphocytes could be found in the depression area. All treatment groups markedly do effects on the cancer models. The best group is NDV+Kanglaite group, then KLT, last NDV. The antitumor mechanism of these three medcines may be that they could level up the functions of immune system and nervous system. Those can inhibit or weak the cancer cell growth.
10. After building the cancer models, 48 cancer models were divided into three groups. Those are NDV group, SW group, NDV+Kanglaite group and control group. The results suggested that the tumors were necrosis, the tumor cells were dissolved and karyopyknosis when time expand. Plenty of lymphocytes could be found in the depression area. All treatment groups markedly do effects on the cancer models. The best group is SW+Kanglaite group, then NDV, last SW. The antitumor mechanism of these three medcines may be that they could level up the functions of immune system and nervous system. Those can inhibit or weak the cancer cell growth rate, make apoptosis or necrosis on tumor cells. So they have effects on the tumors.
本研究通过建立的S37动物肿瘤模型,运用H.E染色、TH染色、NeuN染色、GFAP染色技术和免疫组化SP法研究了三种药物抗肿瘤的效果及其作用机制。
本研究取得以下结果:
1.成功地对中脑神经组织进行了体外培养。试验表明,用1-4d胚鼠中脑组织培养运用基础培养基;5-10d,置换为N4培养基,初级突起和次级突起得到了充分的发育,并由突起形成了网络状结构。
2.将KLT作用于中脑组织培养,表明添加不同浓度KLT作用后,浓度为0.001mg/ml的KLT对多巴胺能神经元具有促进生长的作用,神经元数量增加了13.3%,浓度为0.01mg/ml、0.1mg/ml、1.0mg/ml的KLT作用后,神经元的数量有所下降,表明高浓度KLT对中脑组织有轻微毒害作用,低浓度KLT能够很好地刺激中脑组织神经元的生长。
3.用KLT作用于帕金森症模型中,用不同浓度KLT作用于受损的多巴胺能神经元,结果表明,各浓度KLT稀释液均能显著提升多巴胺能神经元神经元的数量,浓度为0.001mg/ml的KLT比对照度提高了88%。且细胞突起明显变长,次级突起数量增多,胞体圆滑。
4.N18TG2神经母细胞瘤在N4培养基中呈现旺盛生长,胞体变大,伸出几个大的初级突起,初级突起上伸出很多细丝状的次级突起。MTT结果表明在12h,24h和48h,在N4培养基中N18TG2生长速度显著高于NBT培养基中的生长速度,在48h时,N4培养基中的细胞数是NBT培养基中的3倍。
5.实现了胚鼠中脑组织与鼠源神经母细胞瘤N18TG2的共培养。将接种浓度为2.5×104、5.0×104和105 cells/ml的N18TG2神经母细胞瘤细胞接种于中脑神经组织。结果显示,各接种浓度均能在中脑组织中生长,但生长比较缓慢。N18TG2低接种浓度共培养中,神经母细胞瘤对中脑组织细胞几乎无伤害作用,只有高浓度接种的肿瘤细胞才对神经元形成毒害作用,神经元出现胞突变短,胞体肿胀,次级突起消失;神经元数量减少等变化。
6.不同浓度KLT作用于N4培养基和NBT培养基的神经母细胞瘤N18TG2, MTT结果显示,各浓度KLT均对N18TG2神经母细胞瘤的有极显著的抗肿瘤效果。高浓度KLT组中可见到大量的肿瘤细胞碎片,在各种浓度KLT上清液中均能见到大量凋亡小泡,表明KLT对N18TG2神经母细胞瘤的抗肿瘤作用呈现剂量依赖关系,高浓度KLT导致肿瘤细胞发生坏死,低浓度KLT诱导肿瘤细胞凋亡。
7.不同浓度KLT作用于神经母细胞瘤N18TG2细胞与中脑组织共培养中,结果显示,浓度为0.001mg/ml的KLT的肿瘤细胞数在各个时期均显著低于对照组,肿瘤抑制率为36%,且该组神经元的初级突起和次级突起均是完整的,神经元突起构成的网络结构依然清晰。在其他浓度KLT作用下,肿瘤细胞有所减少,但差异不显著。同时在共培养组织中也见到大量呈圆形无突起的神经元细胞,表明在共培养组织中低浓度组KLT具有抑制肿瘤细胞的效果。
8.不同浓度KLT作用于神经母细胞瘤N18TG2细胞与中脑组织共培养中,结果表明,KLT各作用组对多巴胺能神经元、神经元和神经胶质细胞的数量大大增加,且细胞胞体和突起较平滑,突起数目较多,较长,神经元突起构成的网络较清晰。表明KLT能很好地保护中神经细胞。
9.建立了S37肿瘤模型鼠,将48只S37荷瘤小鼠随机分成4组,即对照组、NDV治疗组、康莱特治疗组和NDV联合康莱特治疗组。体内抗肿瘤效果表明,随时间延长,肿瘤组织生长缓慢、肿瘤细胞发生溶解、核固缩、坏死区可见到大量的淋巴细胞,三种药物具有显著地抗肿瘤作用,其中NDV弱毒和康莱特注射液联用组的抗肿瘤效果最好,康莱特组次之,NDV组稍差。其抗肿瘤作用机制有可能是三种药物提高了机体神经系统和免疫系统机能,破坏或减弱了瘤细胞的生长繁殖速度,引起瘤细胞凋亡和死亡,起到了抗肿瘤作用。
10.建立了S37肿瘤模型鼠,将48只S37荷瘤小鼠随机分成4组,即NDV治疗组、苦马豆素组治疗组、NDV联合苦马豆素治疗组和对照组。体内试验结果表明结果表明,随时间延长,肿瘤组织坏死严重、肿瘤细胞发生溶解、核固缩、坏死区可见到大量的淋巴细胞,三种药物具有显著地抗肿瘤作用,其中NDV弱毒和SW联用组的抗肿瘤效果最好,NDV组次之,SW组稍差。其抗肿瘤机制可能与三种药物均能刺激并提高机体免疫系统和神经系统机能,抑制或直接杀伤了肿瘤细胞,诱导肿瘤细胞凋亡或坏死,起到了抗肿瘤作用。
Cancers are the first killer for threatening human healthes. Curing or cancelling tumors is a big problem on the world. While how to cure midbrain system disease and tumors in midbrain such as neuroblastoma and Parkinesons have become as the hottest projects to attack. It’s very important to attack nerve system tumor for leveling up the quality of the sick and extend human life. The operations, chemo-treatment, treatment by Chinese herbs, gene therapy, immunization theropy are used on the patients. Though have some effects but the toxic side effect and expensive curing fees can’t be bearable by the patients and their families. Some patients even give up treatments. To find no toxic side effects and effective new ways for curing cancer is most researchers’wishes. So to study biology factors Chinese herb Kanglaite injection (KLT) influence on the midbrain tissue. Then to study the mechanism of antitumor cooperation of Oncolytic virus New castle disease virus (NDV), KLT and secondary metabolite of Rhizoctonia leguminicola swaisonie (SW). Both researches are what our project want to do.
This research we built S37 models,, H.E staining TH staining,NeuN staining and GFAP staining technical were used in our study for getting more antitumor mechanism informations from threemedicines. The results as follows:
1. The midbrain cultures were successfully built from 14-day old mouse embryos. From 1-5 day the midbrain cultures were maintained in the basic medium and the cell bodies grew bigger and bigger. There are some short processes appeared. From 5-10 days, the midbrain culture medium was changed by N4 medium. Many long processes were sprayed out from the cell bodies and the second processes can be found. And the processes were formed very big network in the cultures. All these mean that midbrain tissue could be grown well outside body.
2. It’s the first time that KLT were used in the midbrain cultures to detect if there is some cytotoxixity on the midbrain cultures. The different dilutions of KLT were added. The results showed that the concentration of 0.001mg/ml could stimulate neurons growing faster and the number of the neurons increased 13.3%. While the number of the neurons in other KLT solutions had some little decrease. All means that higher concentrations of KLT do some harms to midbrain cultures. However the lower concentrations could well stimulate the growth of the neurons.
3. The 200μM MPP+ were used to build Parkinsonismus mould. Different concentrations of KLT were used to do some treatments on the hurted dopaminergic neurons. The numbers of the dopaminergic neurons were counted and statistics and the morphology changes can be seen on the dopaminergic neurons. The concentration of 0.001mg/ml leveled up the number of the dopaminergic neurons 88% in contrast to the control. And the processes of the dopaminergic neurons became more longer and the neutrites possess more to the control. The results showed that KLT could be used to cure the Parkinsonismus.
4. The N18TG2 neuroblastoma cells was the first time to grow in the midbrain culture medium N4 medium to detect if the N18TG2 can be growed in the N4 medium. The morphology changes and MTT assay showed that the N18TG2 can grow very well inside the N4 medium. Many big primary processes showed up and many second processes on the primary. The bodies of the N18TG2 become more bigger and bigger. MTT results suggested that the N18TG2 cells grew more quickly than the N18TG2 inside NBT medium in 12h,24h and 48h. Especially the number of N18TG2 cell in N4 medium is triple to the NBT medium. So the N18TG2 cells can grow in the midbrain medium.
5. It’s the first time that N18TG2 neuroblastoma cells were cocultured with midbrain tissue. The seeding densities of the N18TG2 cells are 2.5×104,5.0×104 and 105 cells/ml and were seeded in the midbrain culture. Take pictures at 12h,24h,36h and 48h separately. The numbers of the tumor cells were counted and statistics and the morphology changes could be found. The results showed that the N18TG2 could grow in the midbrain culture in all seeding densities but grew very slowly. Lower seeding densities N18TG2 cells can’t do cytotoxicity on neurons in midbrain culture. While higher seeding densities made the neuron swell and the processes became shorter and the second processes disappeared. The number of the neurons was decreased.
6. To detect the antitumor effects of KLT on N18TG2 neuroblastoma in N4 medium and NBT medium. The different concentrations of KLT treatments on N18TG2 neuroblastoma were added. The antitumor effect values were detected by MTT assay. The results showed that the KLT treatments have significant antitumor effects contrast to the control either in N4 medium or in NBT medium. Plenty of fragments and many apoptotic vesicles can be found in the culture suspension especially in the higher KLT concentrations. The results suggest that KLT treatments on N18TG2 neuroblastoma are dose dependent on the antitumor effects. And higher KLT solutions can make cancer cells depressed and lower KLT solutions induce apoptosis on N18TG2 neuroblastoma. The inhibition rate of 1.0mg/ml KLT is 48.7%.
7. KLT was used in the coculture for studying the antitumor effects on the N18TG2 neuroblastoma cells. The different KLT solutions were added into the coculture separately for another 48h. The numbers of the tumor cells were counted and statistics and the morphology changes could be found. The results showed that 0.001mg/ml KLT solution possessed significant lowest tumor number in all the tests in different periods to the control. The inhibition rate is 36%. The morphology showed that the primary processes and second processes didn’t been hurted and the networks made by processes were very clear. In other KLT solution treatment, the number of the tumor cells was decreased but not significantly to the control. Many round, no processes neuron could be found in other KLT solutions. These suggest that 0.001mg/ml KLT solution possess antitumor effect in the coculture of midbrain neurons and N18TG2 neuroblastoma.
8.After different solutions of KLT treatments on the coculture of neuroblastoma cells and midbrain cells, the numbers of the dopaminergic neurons, all neurons and astrocytes were counted and statistics and the morphology changes could be found. The morphology showed that the primary processes and second processes didn’t been hurted and the networks made by processes were very clear. The numbers of the dopaminergic neurons, all neurons and astrocytes were increased quickly and the bodies and the processes are very smooth. The decrease of the dopaminergic neurons, all neurons and astrocytes in the control was easy to find. Many apoptotic vesicle can be found in the bodies and the processes. KLT could level up the numbers of the dopaminergic neurons, all neurons and astrocytes and improve the lives of the neurons.
9 After building the cancer models, 48 cancer models were divided into three groups. Those are control group, Kanglaite injection group and NDV+Kanglaite group. The results suggested that the tumors grew very slowly, the tumor cells were dissolved and karyopyknosis when time expand. Plenty of lymphocytes could be found in the depression area. All treatment groups markedly do effects on the cancer models. The best group is NDV+Kanglaite group, then KLT, last NDV. The antitumor mechanism of these three medcines may be that they could level up the functions of immune system and nervous system. Those can inhibit or weak the cancer cell growth.
10. After building the cancer models, 48 cancer models were divided into three groups. Those are NDV group, SW group, NDV+Kanglaite group and control group. The results suggested that the tumors were necrosis, the tumor cells were dissolved and karyopyknosis when time expand. Plenty of lymphocytes could be found in the depression area. All treatment groups markedly do effects on the cancer models. The best group is SW+Kanglaite group, then NDV, last SW. The antitumor mechanism of these three medcines may be that they could level up the functions of immune system and nervous system. Those can inhibit or weak the cancer cell growth rate, make apoptosis or necrosis on tumor cells. So they have effects on the tumors.
引文
白莲花,钱振超.1997.新城鸡瘟病毒诱导巨噬细胞TNF-α基因表达及其继承性抗肺转移作用的实验研究.中国肿瘤生物治疗杂志,4(2):121-4
白莲花,钱振超.1994.新城鸡瘟病毒激活的巨噬细胞抗肿瘤转移作用的研究.上海免疫学杂志,14(6):334-6
白莲花,于春,鲍秋莉,顾芳,李娟,陈乃玲,钱振超.1997.新城鸡瘟病毒诱导人外周血单核细胞产生的一氧化氮与细胞毒依赖作用的研究.中国肿瘤生物治疗杂志,4(3):184-5
鲍英,夏璐,姜华,张学军,袁耀宗.2004.康莱特诱导人胰腺癌细胞凋亡的实验研究.上海医学,27(6):421-4
鲍英,夏璐,姜华,章永平,乔敏敏,张学军,袁耀宗.2005.薏苡仁提取液对人胰腺癌细胞凋亡和超微结构的影响.胃肠病学,10(2):75-8
蔡宝祥.2002.家畜传染病学.北京:中国农业出版社,307
崔成旭,李峻岭,郝学志,王金万,李玉升,屈风莲,赵龙妹,储大同.1998.康莱特联合化疗治疗晚期非小细胞肺癌8例临床观察.实用肿瘤杂志,13(6):376-7
戴淑琴,王军业,马国伟,戎铁华,王欣,林鹏,叶文峰,张兰军,李小东,张旭,姚广裕.2006.康莱特注射液对现代二野清扫术食管癌患者围手术期细胞免疫支持治疗的临床随机对照研究.实用肿瘤杂志,21(6):515-8
董西林,王雅娟.1994.肝癌患者外周血T细胞亚群及免疫细胞活性研究.西安医科大学学报,120(4):474-475,494
龚非力,熊思东.2003.医学免疫学.科学出版社.109-13
古长庆,金宁一.鸡新城疫病毒抗肿瘤作及其机制的研究进展.2000.中国肿瘤生物治疗杂志,7(3):238-240
管国芳,金春顺,金宁一,米志强,李霄,连海,孙丽丽,文连姬,2005.新城疫病毒对Hep-2肿瘤细胞的抑制效应.中国耳鼻咽喉头颈外科,12(8):487-90
管国芳,金春顺,金宁一,张静敏.米志强,李霄,连海,孙丽丽,文连姬,崔葳.2005.新城疫病毒致Hep- 2肿瘤细胞死亡方式的研究.中国生物制品学杂志,18(6):461-4
郭坤元,梅家转,姚开泰.2007.人鼻咽癌细胞株CNE2对NK细胞KIR/NKG2D受体免疫编辑作用及其对NK细胞杀伤功能的影响.南方医科大学学报,27(3):247-9
郭坤元,梅家转,姚开泰,吟晓林.2007.NK细胞免疫编辑后的人鼻咽癌细胞株CNE2 HLAⅠ类分子和MICA/MICB的表达及其对NK细胞杀伤活性的影响.第四军医大学学报,28(11):1005-7
郭坤元,梅家转,姚开泰,尹晓林.2007.NK细胞免疫编辑后的人鼻咽癌细胞株CNE2HLAⅠ类分子和MICA/MICB的表达及其对NK细胞杀伤活性的影响.第四军医大学学报,28(11):996-8
郝光荣.1999.实验动物学.陕西人民卫生出版社,76
侯冰宗,李绵,刘泓基,志伟.1999.康莱特对晚期大肠癌患者NK细胞活性、sIL-2R、TNF-α影响的研究.实用肿瘤杂志,14(6):382-83
胡建兵,翁洁,刘颂莲.2003.康莱特联合介入化疗栓塞治疗中晚期肝癌疗效观察.陕西肿瘤医学,11(1):48-49
黄挺,陈震,杨雪飞,李勇,张志娣,黄伶,张建刚,张晓丽.2008.康莱特注射液抗恶性肿瘤肝转移疗效及机制的实验研究.中国现代应用药学杂志,25(1):13-15.
姜晓玲,张良,郭成.2000.康莱特注射液对血管生成的影响.肿瘤杂志,20(4):313-314
蒋晓山.1991.NDV-沙榄香烯瘤苗的临床应用及免疫效果的近期评价(附8例报告).大连医学院学报13(4):1-4
李炳生,陈秀华,任文龙,陆宏祺,姚玉龙,严惠芳.1998.康莱特注射液的抗肿瘤作用.中国医药工业杂志,29(10):456-8
李大鹏.2001.康莱特注射液抗癌作用机理研究进展.中国新药与临床药理,12(2):122-4
李健强,李六金.1991.兽医微生物学实验实习指导.陕西:陕西科学技术出版社.
李同度,刘爱国.1999.康莱特注射液控制癌痛及提高晚期癌症患者生存质量III期临床研究.中国肿瘤临床,26(5):372-6
李同度,刘爱国.1998.康莱特抗癌症恶病质实验研究.中国肿瘤临床,25(2):131-3
李学,吴晓秀,李佩文.1999.康莱特注射液治疗原发性肝癌的临床研究.中国肿瘤临床,26(6):475-6
李瑛.2002.康莱特诱导肿瘤细胞凋亡的实验研究.中国肿瘤临床,40(12):37-41
李瑛,焦顺昌,孙胜杰,魏秀芳.2005.康莱特注射液与泰素帝合用对肺癌细胞的增敏作用研究.中药新药与临床药理,16(6):424-6
李瑛,石廷章.2002.康莱特诱导肿瘤细胞凋亡的实验研究.中国肿瘤临床,29(12):869-73
李瑛,石廷章,魏秀芳.2001.康莱特诱导HL60细胞凋亡的实验研究.实用癌症杂志,16(1):9-10
梁铁军,秦成勇,谭艳蓉,蒋莹,赵小栖.2006.康莱特抑制肝癌细胞HepG2增殖的实验研究.中国肿瘤临床,33(13):23-6
梁智勇,王文泽,高洁,刘彤华.2006.康莱特注射液合并健择对移植于裸鼠的人胰腺癌的疗效初步研究.中华肿瘤防治杂志,13(3):177-80
刘剑仑,埃高莫·比佐,韦长元,唐东平,李挺.2001.康莱特注射液诱导人肝癌细胞凋亡的研究.实用癌症杂志,16(4):343-7
刘科耀,胡龄鹤,曾书标.1994.新城疫苗对鼻咽癌疗效的初步实验研究.耳鼻咽喉一头颈外科,1(3):171-173
刘炳亚,林言箴,尹浩然.1998.苦马豆素抑制胃癌生长及转移的实验研究.中华肿瘤杂志,20(5):168-70
刘苗生,王崇宇. 2006.康莱特增强中晚期食管癌患者对放疗的耐受性.现代肿瘤医学,14(5):566-67
刘名光,邝国乾,岳惠芬,等.1995.新城疫病毒IV系疫苗抗小鼠移植瘤作用的实验研究.广西医科大学学报,12(2):197
刘名光,邝国乾,岳惠芬,梁新强.1995.新城疫病毒La Sota株疫苗免疫治疗小鼠移植瘤的生存期观察.医学文选,16(2):112-3
刘名光,邝国乾,黎福祥,黄菊,张奕敬,岳惠芬,梁新强,杨南武,崔英.2000.新城病毒疫苗吸入接种效应及其对鼻咽癌患者的辅助疗效观察.癌症,19(10):912-5
刘名光,梁新强.2001.新城疫病毒诱导的抗体反应与肿瘤生长的相关分析.14(2):72-4
卢志平,罗和生,张法灿.2007.康莱特注射液联合三维适形放疗治疗中晚期肝癌.中国医学文摘老年医学,16(1):40-43.
罗荣辉,刘婉华,刁振琦,陈香才,张丽.2001.光动力疗法对肝癌小鼠的抗肿瘤及免疫效应研究.应用激光,21(3):211-13
梅家转,周健,郭坤元,魏红梅.2006.低表达MICA/MICB导致NK细胞对人鼻咽癌多药耐药细胞(CNE2/DDP)杀伤活性下降.中国肿瘤生物治疗杂志,13(5):349- 52
梅家转,郭坤元,吴远彬,周健,魏红梅.2007.同种异体NK细胞对人多药耐药鼻咽癌细胞裸鼠皮下移植瘤的抑制作用.中国肿瘤生物治疗杂志,14(3):249- 53
米志强,金宁一,龚伟.2003.pVVP3和pVHN核酸疫苗的构建、表达及对肿瘤细胞的作用.中国生物化学与分子生物学报,19(6):704-8
潘李珍.1997.新城疫弱病毒对人肺腺癌细胞系A549多细胞球体的作用.首都医科大学学报,18(3):209-13.
彭晓赤,缪荣金.2006.康莱特注射液对晚期癌症患者生存质量的影响.癌症进展杂志,4(3):263-65
朴炳奎,李佩文,吴良村,等.1998.康莱特注射液治疗原发性支气管肺癌III期临床总结/李大鹏.康莱特抗肿瘤的研究论文集.浙江浙江大学出版社,152-68.
钱明山,张才良.1998.康莱特注射液介人治疗原发性肝癌和原发性肺癌的临床研究/李大鹏康莱特抗肿瘤的研究论文集.浙江浙江大学出版社,214-29
山长平,杨秀芹,崔巍,郭恒照.2007.康莱特注射液联合小剂量化疗治疗晚期胰腺癌的临床观察.中药新药与临床药理,18(1):72-73
单虎,郭鑫,1998.新城疫病毒在鸡胚不同组织增殖的研究.中国畜禽传传染病20(3):144-6
单虎,王述柏,郭鑫,等.1998.新城疫病毒在鸡胚同组织增殖的研究.中国畜禽传染病,20(3):144-46
沈顺华,尹思源,吴汉林.2006.康莱特对大肠癌HT-29细胞株体外生长抑制作用的研究.实用肿瘤杂志,21(6):531-33
申文江,温昭信,沙永慧.1998.康莱特注射液联合放射治疗恶性肿瘤临床研究/李大鹏康莱特抗肿瘤的研究论文集.浙江浙江大学出版社,198-203
沈霞芬.2001.动物组织学与胚胎学.中国农业出版社.
石星,丁乾,王晶.2006.康莱特注射液联合化疗治疗晚期消化道肿瘤.中国中西医结合消化杂志,14(4):249-51
苏雁欣,陈英淮,康向华,李树祥.2000.新城疫病毒疫苗对小鼠S180肉瘤抑瘤作用的实验研究.34(1):15-17
孙丽亚,张立新,张立敏,李春海.1999.康莱特注射乳剂对MUC1粘蛋白表达的影响及其生物学意义.实用肿瘤杂志,14(6):380-2
唐省三,马亚珍.2004.新城疫病毒体内外抗肿瘤作用的研究.陕西医学杂志,33(12):1093-5
唐省三,马亚珍.2005.新城疫病毒对体外培养人膀胱癌EJ细胞凋亡机制研究作用.陕西医学杂志,34(5):521-4
陶厚权.1997.抗癌药Swainsonine的基础与临床研究进展.国外医药-合成药、生化药、制剂分册,18(1):34-36
陶厚权.1996.抗癌药Swainsonine的实验与临床研究进展.中国肿瘤临床,23(11):822-4
田玉山,贾维真.1989.组织学技术.陕西:西北农业大学.
王俊杰,孙新臣,申文江,俞莉章,于世平.1999.康菜特注射液诱发肾癌细胞凋亡及P53,bal-2表达的研究.中国肿瘤临床,26(6):439-42
王秀荣,王秀英,冯惠东.2005.白细胞介素-15协同新城疫病毒HN基因抗肿瘤免疫的作用.四川大学学报,36(2):284-5
王越华,李兆元,龚先奇.2006.康莱特注射液联合化疗治疗晚期结直肠癌.肿瘤,26(12):1137-8
王兆太,董光龙,王为忠.2002.康莱特注射液对胃癌患者细胞凋亡增殖及T细胞亚群的影响.细胞与分子免疫学杂志,18(5):463-5
魏林,戴建新,傅传刚.2001.新城疫病毒HN基因对肿瘤抗原诱导的抗肿瘤免疫的增强作用.中华微生物学和免疫学杂志,2l(6):619-22
魏林,戴建新,孙树汉.2000.新城疫病毒HN基因真核表达质粒的构建及其抗肿瘤作用的初步研究.第二军医大学学报,21(6):515-8
薛立娟,龚伟,葛涛,王宏伟,罗琴芳,孙大辉,李萍,金宁一.2002.新城疫病毒plRHN核酸疫苗构建和表达及对肿瘤细胞的影响.中国免疫学杂志,18(5):338-40
薛立娟,金宁一,龚伟,王宏伟,孙大辉,罗琴芳,葛涛,李萍.2003.新城疫病毒对肿瘤细胞生物学行为的影响.细胞与分子免疫学杂志.19(1):29-34
杨汉春,姚火春,王君伟,等.2003.动物免疫学.中国农业大学出版社,66-94
杨骅,王平,郑树.1998.康莱特抗肿瘤的研究论文集.浙江大学出版社,110-14
杨骅,王仙平,郑树,等.1998.康菜特抗肿瘤的研究论文集.浙江大学出艋社,115-18
杨骅,王仙平,郑树.1998.康莱特抗肿瘤的研究论立集.浙江大学出版社,107-9
杨惠玲,潘景轩,吴伟康.2000.高级病理生理学.科学出版社,:354-453,482-498
杨鸣琦.1997.豆类丝核菌苦马豆素提取及其抗肿瘤作用初步研究.陕西杨凌:西北农林科技大学
杨鸣琦,曹光荣.1997.苦马豆素的毒性、代谢与用途.动物医学进展,18(4):20-25
杨鸣琦,张黎,周宏超,路宏朝,黄增荣.2003.豆类丝核菌次级代谢产物抗肿瘤作用的病理学观察.西北农业学报,12(4):5-7
杨鸣琦,张黎,周宏超,黄增荣,路宏朝.2003.豆类丝核菌次级代谢产物的抑瘤作用及其对荷瘤小鼠巨噬细胞活性的影响.西北农林科技大学学报(自然科学版),31(Z1):55-8
杨志刚,曾耀英,何贤辉,王青,江逊.2004.NK细胞对小鼠异基因骨髓移植造血及免疫重建的影响. 中华血液学杂志,25(12):713-6
杨志刚,曾耀英,何贤辉,王通,王青.2004.NK细胞在小鼠异基因骨髓移植中的作用.中国病理生理杂志,20(9):1563-7
殷震,刘景华.1997.动物病毒学.第2版.北京:科学技术出版社,736-67
殷震,刘景华.1985.动物病毒学.北京科学出版社,674
姚莉,姚冬青.2007.康莱特改善晚期癌症患者生存质量的临床研究.中国药师,10(1):33-5
姚淑莲,成涛,宁亚利.2006.康莱特注射液改善老年晚期消化道肿瘤的临床症状分析.肿瘤,26(4):387-8
姚玉龙,陈秀华,任文龙,卢艳萍,戴静芝,李炳生.2002.康莱特软胶囊对小鼠的免疫促进作用研究.中药新药与临床药理,13(4):233-5
岳惠芬,邝国乾,刘名光,梁新强,黄菊,杨甫武.2000.IV型鸡新城疫苗升高恶肿病人白血球水平作用的研究.广西医学,22(1):22-3.
张爱琴,马胜林,孙在典,包素珍.2007.康莱特注射液对Lewis肺癌小鼠免疫功能的影响.浙江中西医结合杂志,17(4):199-200
张海青,李世业,付瑜,杨声,富延海,秦明,吕福东,闫东杰.等.1999.康莱特注射液治疗原发性肺癌的临床及病理学观察.中国肿瘤临床,26(6):477-8
张宏宇,白莲花,刘学仁.1995.新城鸡瘟病毒修饰的同种肿瘤细胞对肿瘤转移免疫防治效应.中华微生物学和免疫学杂志,15(1):19
张黎,杨鸣琦,黄增荣,路宏朝.2004.豆类丝核菌次级代谢产物对荷瘤小鼠T淋巴细胞活性的影响.军医进修学院学报,25(2):164-6
张萍,付兴华,彭军,马立人.2006.新城疫病毒诱导人自然杀伤细胞杀伤喉癌细胞株Hep-2的体外研究.中国现代医学杂志,16(4):512-5
张琪.2010.NDV弱毒苗与SW或polyiC联用对小白鼠移植性肿瘤S37的抑制作用研究,西北农林科技大学学报自然科学版,25(9):34-9
张守信,曹光荣,李绍君.1992.甘肃棘豆醇提物对小鼠移植性肿瘤S37、H22的抑制试验.畜牧兽医杂志,2:13-15.
中国科学院南京土壤研究所编著.1985.土壤微生物研究方法.科学出版社
张铁英,褚敏,倪志强,张扬.2007.康莱特可有效提高晚期恶性肿瘤患者的生存质量.实用肿瘤杂志,22(6):540-41
郑毛根,赵艾君,陈志全.2006.康莱特联合放疗对75岁以上未手术的老年食管癌患者安全性与疗效的评价.中国老年杂志,8(26):1127-8
A Asada T.1997.Treatment of human cancer with mumPs virus.Cancer34 (6):1907-28.
Aharinejad S,D Abraham ,P Paulus ,H Abri ,M Hofmann ,K Grossschmidt , R Sch?fer ,E R Stanley ,R Hofbauer. 2002.Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xengraft in mice. Cance Res, 62(18):5317-24.
Ahlert T, W Sauerbrei, G Bastert. 1997. Tumor cell number and viability as quality and efficacy parameters of autologous virus modified cancer vac2 cines in patients with breast or ovarian cancer.J Clin Oncol,15(7):2763
Ahmadzadeh M, S A Rosenberg. 2005.TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells.J Immunol,174(9):5215-23.
Alessandro P, R Z Maria.2006. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. Arch I mmunol Ther Exp, 54(5):323-33
Andre P, O Spertini, S Guia, P Rihet, F D Gerorge, H Brailly, J Sampol, P J Anderson, E Vivier. 2000. Modification of P-selectin glycolprotein ligand21 with natural killer cell-restricted sulfated lactosamine creates an alternate ligand for L2 selectin. Proc Natl Acad Sci USA ,97(7):3400-5
Aptsiauri N, T Cabrera,R Mendez, A Garcia-Lor, F Ruiz-Cabello, F Garrido. 2007. Role of altered expression of HLA class Imolecules in cancer progression. Adv Exp Med Biol, 601(4):123-31
AsadaT.1974.Treatment of human cancer with mumps virus.Cancer,34(6):1907-28
Asai O,D L Longo,Z G Tian,R L Hornung ,D D Taub ,F W Ruscetti ,W J Murphy . 1998.Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow t ransplantation. J Clin Invest, 101(9):1835-42
Bacchetta R,C Sartirana,M K Levings,C Bordignon, S Narula,M G Roncarolo.2002. Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur J Immunol,32(8):2237-45.
Bamusheng. 1989. Anti tumor and anti inflammation effects of Coix seed .World Med: Phytomed, 4(2):75-77
Bar-EliN,H Giloh,M Schlesinger.1996. Preferential cytotoxic ef fect of Newcastle disease virus on lymphoma cells .J Cancer Res Clinincol. 122 (7):409-41
Barry M, R C Bleackley. 2002. Cytotoxic T lymphocytes :all roads lead to death. Nat Rev Immunol,2(6):401-409
Bat liwalla F W, B A Bateman,D Serrano. 1998. A 15 year follow up of AJCC stage III malignanmelanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate andetermination of alterations in the CD8 T cell repertorie. Mol Med, 4(12):783-94
Bauer T M,L P Jiga,J J Chuang,M Randazzo,G Opelz,P Terness.2005.Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl Int,18:95-100
Baume D M, M J Robertson, H Levine, T J Manley, P W Schow, J Ritz. 1992 . Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. Eur J Immunol, 22 (1):1-6
Beard C W, R P Hanson. 1984. newcastle diease in disease of poultry. lowa state university press, 452-70
Beierle E A,L F Strande,M K Chen. 2002. VEGF upregulates Bcl-2 expression and is associated with decreased apoptosis in neuroblastoma cells. J Pediatr Surg,37(3):467-71
Bianh,P Fournier,R Moormann. 2005. Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus. Cancer Gene Ther, 12:295-303
Bianh,P Fournier,B Peeter. 2005. Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein . International Journal of Oncology, 27:377-84
Huang B ,P Y Pan, Q S Li,A I Sato,D E Levy,J Bromberg,C M Divino, S H Chen. 2006. Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing. Host Cancer Res, 66(2):1123-31.
Bottino, Cristina, S Sivori, L Moretta,A Moretta, R Biassoni. 2000. Identification and molecular characterization of a natural mutant of the p50.2/KIR2DS2 activating NK receptor that fails to mediate NK cel triggering.European Journal of Immunology,30(12):3569-74
Bowlin T L,P S Sunkara.Swainsonine.1988.an inhibitor of glycoprotein processing,enhances mitogen induced interleukin-2 production and receptor expression in human lymphocytes. Biochem BioPhys Res Commun,151:486-59
Breton P,A Asseffa,K Grzeorzewski.1990.Swainsonine modulation of protein kinase C activity in murine pevitoneal macrophages.Cancer Commun, 2(10):333-338
Brutkiewicz R R, V Sriram. 2002. Natural killer T (NKT) cells and their role in antitumor immunity. Crit Rev Oncol Hematol,41(3):287-98
Byrne S N,J Ahmed,G M Halliday. 2005. Ultraviolet B but not A radiation activates suppressor B cells in draining lymph nodes. Photochem Photobiol, 81(6):1366-70
Caligiuri M A, C Murray, M J Robertson, E Wang, K Cochran, C Cameron, P Schow, M E Ross, T R Klumpp, R J Soiffer. 1993. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest ,91(1):123-32
Caligiuri M A, A Zmuidzinas, T J Manley, H Levine, K A Smith, J Ritz. 1990. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors . J Exp Med, 171(5):1509-26
Carnaud C, D Lee, O Donnars, S H Psrk, A Beavis,Y Koezuka, A Bendelac. 1999. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol, 163(9):4647-50
Cassel W A, R Earl Garrett. 1965. Newcastle disease virus as antineoplastic agent.Cancer, 18(7):863-8
Cassel W A, D R Murray. 1988. Treatment of stageⅡmalignant melanoma Patients with a Newcastle disease virus oncolysate.Nat Immun Cell Growth Regul,7(5-6):351-2
Cassel W A,D R Murray.1992. A ten-year follow-uP on stage II malignant melanoma Patients treate postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacothe, 9(4):169-71
Catlett-Falcone R,T H Landowski,M M Oshiro,J Turkson, A Levitzki,R Savino, G Ciliberto ,L Moscinski ,J L Fernández-Luna ,G Nu?ez ,W S Dalton ,R Jove . 1999. Constitutive activation of stat3 signaling confers resistance to apoptosis in human U266 myeloma cells . Immunity, 10(1):105-15
Cesana G,G DeRaffele,S Cohen,D Moroziewicz, J Mitcham, J Stoutenburg, K Cheung,C Hesdorffer, S Kim-Schulze, H L Kaufman. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 (IL-2) for metastatic melanoma and renal cell carcinoma.J Clin Oncol 24(7):1169-77
Chang H C, Y C Huang, W C Huang. 2003. Antipro liferative and chemop reventive effects of adlay seed on lung cancer in vitro and in vivo . J Agric Food Chem , 51(12): 3656-60
Chao K H, M Y Wu, C D Chen, J H Yang, Y S Yang, H N Ho. 1999. The expression of killer cell inhibitory receptors on natural killer cells and activationstatus of CD4+ and CD8+ Tcells in the deciduas of normal and abnormal early pregnancies. Hum Immunol, 60(9):791-7
Chiang W C, C Y Cheng, M T Cihang, K T Chung. 2000. Effects of dehulled adlay on the cultue count of some microbiota and their metabolism in the gastrointestinal track of rats.J Agric Food Chem , 48(3): 829-32
Cologate S M, P R Dorling, C R Huxtable.1979.A spectroscopic inestigation of swainsonine:an α-mannosidase inhibitor isolated from swaisona canescons J Chem,32:2257-64
Colombo M P,S Piconese. 2007. Regulatory T-cell inhibition versus depletion:the right choice in cancer immunotherapy. Nat Rev Cancer, 7:880-7
Contini P, M Ghio, A Poggi, G Filaci, F Indiveri, S Ferrone, F Puppo. 2003. Soluble HLA-A,-B, -C and -G molecules induce apoptosis in T and NK CD8Tcells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol, 33(5):125-34
Coudert J D, J Zimmer, E Tomasello, M Cebecauer, E Vivier, W Held. 2005. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand2 expressing tumor cells. Blood, 106(5):1711-7
Csatary L K, S Eckhardt, I Bukosza,F Czegledi, C Fenyvesi, P Gergely, B Bodey, C M Csatary. 1993. Attenuated veterinary virus vaccine for the treatment of cancer.Cancer Detect Prev,l7(6):619-27
Csatary L K. 1971 .Viruses in the treat me nt of cancer .Lancet, 2 :825
Csatary L K,R W Moss, J Beuth. 1999. Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine(MTH - 68/H)Anticancer Res19 (1B):635-8
Cui J,T Shin,T Kawano,H Sato,E Kondo,I Toura,Y Kaneko,H Koseki,M Kanno, M Taniguchi.1997. Requirement for Va 14 NKT cells in IL-12-mediated rejection of tumors.Science,278:1623-6
Chang D H, K Osman, J Connolly, A Kukreja,J Krasovsky, M Pack, A Hutchinson, M Geller,N Liu, R Annable, J Shay, K Kirchhoff, N Nishi, Y Ando, K Hayashi, H Hassoun, R M Steinman, M V Dhodapkar. 2005. Sustained expansion of NKT cells and antigen-specific T cells after injection of a-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med, 201(9):1503-17
Daniluk J,M K Szerszen,L Borowska.1996. Tumor necrosis factor and interfere on production by peripheral blood leukocytes of patients with alcoholic cirrhosis. Arch Immunol Ther ExP Warsz,44(2-3):97-101
David H C, K Osman, J Connolly, A Kukreja, J Krasovsky, M Pack,A Hutchinson, M Geller, N Liu, RAnnable, J Shay, K Kirchhoff, N Nishi,Y Ando, K Hayashi, H Hassoun,M Ralph, Steinman,V Madhav, Dhodapkar. 2005. Sustained expansion of NKT cells and antigen-specific T cells after injection of a-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med, 201(9):1503-17
Del-Val M, D Lopez. 2002. Multiple proteases process viral antigens for presentation by MHC class I molecules to CD+8 Tlymphocytes. MolImmunol, 39(3-4):235-47
Dennis N. 2003. The new face of traditional Chinese medicine.S cience, 299(10):188-90
Dennis J W, K Koch, D Bechner. 1989. Inhibition of human HT29 colon carcinoma growth in vitro and in vivo by swainsonine and human imerferon-α2. Natl Cancer Inst,81:1028-30
Dennis J W,K Koch,Youscfis. 1990.Growth inhibition of human melanoma tumor xenogralts in athymic mice by soainsonine.Cancer Res,50:1867-9
Dennis J W,S L White,A M Freer. 1993. Carbonoyloxy analogs of the anti-metastatic drug swainsonine .Biochem Pharmacol,46(8):1459-66.
Di Santo J P,C A Vosshenrich. 2006. Bone marrow versus thymic pathways of natural killer cell devel opment . I mmunol Rev, 214(11):35- 46
Doubr ovina E S, M M Doubrovin, E Vider, R B Sisson, R J O'Reilly, B Dupont, Y M Vyas. 2003.
Evasion from NK cell immunity by MHC classⅠchain-related molecules expressing colon adenocarcinoma. J Immunol, 171(12):6891-9
Dunn G P,C M Koebel,R D Schreiber. Interferons, immunity and cancer immunoediting .2006. Nat Rev I mmunol, 6(11):836-48
Dunn G P, L J Old,R D Schreiber. 2004.The three Es of cancer immunoediting . Annu Rev Immunol, 22:329-60
DziadK S,C G Espinoa,H Kunz. 2003. Synthetic glycopeptides for the development of antitumor vaccines. Aust J Chem, 56:519-43
Eberl G,H R MacDonald. 1998. Rapid death and regeneration of NKT cells in anti-CD3epsilon- or IL-12-treated mice: a major role for bone marrow in NKT cell homeostasis. Immunity, 9(3):345-53
Ellis T M, R I Fisher. 1989. Functional heterogeneity of Leu 19“bright”+ and Leu19“dim”+ lymphokineactivated killer cells. J Immunol, 142(3):2949-54
Emoto M, S H Kaufmann. 2003. Liver NKT cells: an account of heterogeneity. Trends in Immunol,24(7):364-9
Ensor C M,F W Holtsberg,J S Bomalaski,Clark. 2002. Pegylated arginine deiminase (ADI-SS PEG20, 000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res, 62:5443-50
Farinha P,H Masoudi, B F Skinnider, K Shumansky, J J Spinelli, K Gill,R Klasa , N Voss, J M Connors, R D Gascoyne. 2005. Analysis ofmultiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma ( FL ). Blood,106(6):2169-74
Feng G, Q Z Kong, D S Huang, T Huang, H D Lu, Y Fei, J P Feng. 2004. Experimental Study on Inhibiting Angiogenesis in Mice S180 Sarcoma by Coix Lacryma-Jobi Injection . Cancer ResPrev Treat, 31(4):229-30
Florenes V A,N Bhattacharya,M R Bani,Y Ben-David,R S Kerbel,J M Slingerland. 1996. TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation betweenp21Cip1/ WAF1 and p27Kip1 in a human melanoma cell line lacking p15INK4B:evidence forcooperation betweenp21Cip1/ WAF1 and p27Kip1. Oncogene, 13(11):2447-57
Gajewski T F,Y Meng, C Blank, I Brown,A Kacha, J Kline, H Harlin. 2006. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev, 213(1):131-45
Gansuvd B, M Hagihara, Y Yu, H Inoue, Y Ueda, T Tsuchiya, A Masui, K Ando, Y Nakamura, N Munkhtuvshin. 2002. Human umbilical cord blood NK T cells kill tumors by multiple cytotoxic mechanisms. Hum. Immunol. 63(3):164-75
Gao W W, Y J Zhao,C N He. 2006. Survey of research on germp lasm resources of Coix L .in China. China Tradit Herb Drugs,37(2):293-5
Gazzaniga S,A I Bravo, A Guglielmotti, N van Rooijen, F Maschi, A Vecchi, A Mantovani, J Mordoh, R Wainstok. 2007. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft.J Invest Dermatol,127(8):2031-41
Giraudo E,M Inoue, D Hanahan. 2004. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest, 114(5):623-33
Glass B, L Uharek, M Zeis, H Loeffler, W M Ruchholtz, W Gassmann. 1996. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells. Br J Haematol, 93(2):412-20
Godfrey D I,K J Hammond,L D Poulton,M J Smyth, A G Baxter. 2000. NKT cells:facts,functions and fallacies.Immunol Today, 21(11):573-83
Gorelik L,R A Flavell. 2001. Immune-mediated eradication of tumors through the blockade of transfor ming growth factor-beta signaling in T cells. Nat Med, 7:1118– 22
Granerus M,W Engstrom. 2000. The effects of glycosylation inhibitors on proliferation of a wilms tumor cell line.Anticancer Res,20(2A):689-92
Groh V,R Rhinehart,R Habecker,M S Topp,S R Riddell,T Spies. 2001.Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol, 2(3):255-60
Groh V,A Steinle,S Bauer, T Spies. 1998. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science, 279 (5357):1737-40
Grzegorzewski K,S A Newton,Akiyamask. 1989. Induction of macroPhage tumoricidal activity,major histo comPatibility comPlex classⅡantigen(Iak) expression,and interleukin-1 Production by swainsonine.Cancer Commun,1:373-9
Guan C S, P Yi , Y J Liu, Z Chen. 2001.Clinical study on the effect of Coicis Semen injection on primary hepatic cancer.Ch J Integr Tradit Digest ,9(6):355-6
Guha-Thakurta N,J A Niajde.1997. Early induction of Proinflammatory Cytokinc and Type I interferon mRNAs Following Newcastle disease virus,PolyI [iI : rC ],or low dose LPS challenge og the mouse . J Interferon Cytokinc Res,17(4):197
Guiducci C,A P Vicari,S Sangaletti,G Trinchieri, M P Colombo. 2005. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res, 65(8):3437-46
Gumperz J E. 2004. CD1d-restricted“NKT”cells and myeloid IL-12 production: an immunological crossroads leading to promotion or suppression of effective anti-tumor immune Responses. J Leukoc Biol, 76(2):307-13
Hagemann T, S C Robinson,M Schulz, L Trümper,F R Balkwill,C Binder. 2004. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophagesis due to TNF-αdependent up-regulationof matrix metalloprotease. Carcinogenesis, 25(8):1543-9
Hasselblom S, U Hansson, M Sigurdardottir, H Nilsson-Ehle, B Ridell, P O Andersson. 2008. Expression of CD+68 tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. Pathol I nt, 58(8):529-32
Hass C,C Ertel ,S R Gerhard. 1998. Introduction of adhesive and costi mulatory immune functions into tumor cells by infection with Newcastle disease virus. Int J Oncol, 13 (6):1105-15
Haas C,V Schirrmacher. 1996. Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies. Cancer Immunol Immunother,43(3):190-94
Hasselblom S,U Hansson, M Sigurdardottir, H Nilsson-Ehle, B Ridell, P O Andersson. 2008. Expression of CD+68 tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. Pathol Int, 58(8):529-32
Hayakawa Y, N D Huntington, S L Nutt, S L Nutt, M J Smyth. 2006. Functional subsets of mouse natural killer cells. Immunol Rev, 214(1):47-55
Hayakawa Y, K Takeda, H Yagita, S Kakuta, Y Iwakura, L V Kaer, I Saiki, K Okumura. 2001. Critical contribution of IFN-a and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of α-galactosylceramide. Eur J Immunol,31(6):1720-7
Hayakawa Y, K Takeda, H Yagita, L Van Kaer, I Saiki, K Okumura. 2001. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J Immunol, 166(10):6012-8
Hermans I F, J D Silk, U Gileadi, M Salio, B Mathew, G Ritter, R Schmidt, A L Harris, L Old, V Cerundolo. 2003. NKT Cells Enhance CD4+ and CD8+ T Cell Rdsponses to Soluble Antigen In Vivo through Direct Interaction with Dendritic Cells.J Immunol,171(10):5140-7
HE Webb, C E Gordon Smith. 1970. Viruses in the treatment of cancer.Lancet, 295(7658):1206-9
Hidaky Y,T Kaneda,N Amino,Miyai, K. 1992. Chinese medicine,Coix seeds increase peripheral cytotoxic T and NK cell.Bio therapy,5(3):201-3
Hirano F,K Kaneko,H Tamura, H Dong, S D Wang, M Ichikawa, C Rietz, D B Flies, J SLau,G F Zhu,K Tamada, L P Chen. 2005. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeuticimmunity. Cancer Res, 65:1089-96
Holdenrieder S,P Stieber,A Peterfi,D Nagel, A Steinle, H R Salih. 2006. Soluble MICA in malignant diseases. Int J Cancer, 118(3):684-7
Hong S,D C Scherer,N Singh, S KMendiratta, I Serizawa, Y Koezuka,L Van Kaer. 1999. Lipid antigen presenta-tion in the immune system: lessons learned from CD1d knock-out mice. Immunol Rev,169:31-44
Houri J J,E Ogier-Denis,C Bauvy. 1992. swainsonine is a useful tool to monitor the N-linked glycoprotein as a function of the state of enterocytic differentiation of HT-29 cells.Eur J Biochem,205(3):1169-74
Hsu K C,C A Keever-Taylor,A Wilton,C Pinto, G Heller, K Arkun,R J O'Reilly, M M Horowitz,B Dupont. 2005. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood, 105(12):4878-84
Huang M O, T Liu, P Yuan. 2006. Observation of the therapeut effects of Kanglaite injection combined with chemotherap drug on advanced pulmonary carcinomas.Chin J Misdia , 6 (2):251-2
Huang W C, H C Chang. 2003. Methanolic extract osadlay seed suppresses COX-2 expression of human lung cancer cells via inhibition of gene transcription.J Agric FOOD Chemistry, 51(25):7333-7
Huang X,J Zhu,Y Yang. 2005. Protection against autoimmunity in nonlymphopenic hosts by CD4+CD25+regulatory T cells is antigen-specific and requires IL-10 and TGF-beta. J Immunol, 175(7):4283-91
HumPhries M J,K Mstsumoto,S L White. 1990. An assessment of effects of swainsonine on survival of mice injected with B16-F10 melanoma cells.Clin ExP Metastasis,8(1):89-102
Ibrahim R,H Frederickson,A Parr,Y Ward,J Moncur,S N Khleif. 2006. Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism. Cancer ,106 (5):1065-77
Iero M,R Valenti, VHuber,P Filipazzi,G Parmiani,S Fais,L Rivoltini. 2008. Tumour-released exosomes and their implications in cancer immunity.Cell Death Differ, 15(1):80-8
Ishikawa A, S Motohashi,E Ishikawa,H Fuchida,K Higashino,M Otsuji, T Iizasa, T Nakayama,M Taniguchi, T Fujisawa. 2005. A phase I study of a-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res, 11(5):1910-17
Ito Y, Y Nagai, K Maeno. 1982. Interferon production in miouse spleen cells and mouse fibroblasts(L cells) stimulated by various strains of Newcastle disease virus. J Gen virol, 62:349-52
Jackson M W,J S Roberts,S E Heckford, C Ricciardelli, J Stahl, D J Horsfall, W D Tilley. 2002. A potential autocrine role for vascular endothelial growth factor in prostate cancer.Cancer Res, 62:854-9
JargalsaikhanDagvadorj,YoshikazuNaiki,GantsetsegTumurkhuu,FerdausHassan,ShamimaIslam,NaokiKoide,IsamuMori,TomoakiYoshida,andTakashi Yokochi.2008. Interleukin-10 inhibits tumor necrosis factor-αproduction in lipopolysaccharide-stimulated RAW 264.7 cells through reduced MyD88 expression. Innate Immunity , 14(2):109-15
Jiang W Z, M L Xu ,R B Su. 2000. Evaluation of the accessory anti-tumor effect of adlay processing food .J Health Sci, 2(2):113-22
Jinushi M, T Takehara, T Tatsumi, N Hiramatsu, R Sakamori, S Yamaguchi, N Hayashi. 2005. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol, 43(6):1013-20
Jinushi M, T Takehara, T Tatsumi, T Kanto, T Miyagi, T Suzuki, Y Kanazawa, N Hiramatsu, N Hayashi. 2004. Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to the altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol, 173(10):6072-81
Joon Yun A,K A Bazar,P Y Lee. 2004. Tumors may modulate host immunity partly through hypoxia-induced sympathetic bias.Med Hypotheses, 63(2):352-6
Argilés J M, S Busquets, A Felipe,F J López-Soriano. 2005. Molecular mechanisms involved in muscle wasting in cancer and ageing:Cachexia revsus sarcopenia.Int J Biochem cell Biol,37(5):1048-104
Kaplan D H,V Shankaran,A S Dighe,E Stockert,M Aguet,L J Old,R D Schreiber. 1998.Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA, 95(13):7556-61.
Kawano T, J Q Cui,Y Koezuka, I Toura, Y Kaneko, H Sato, E Kondo, M Harada, H Koseki, T Nakayama, Y Tanaka, M Taniguchi. 1998. Natural killer-like nonspecific tumor cell lysis mediated by specific ligandactivated Vα14 NKT cells. Proc Natl Acad Sci USA, 95(10):5690-93
Kawano T, T Nakayama, N Kamada, Y Kaneko, M Harada, N Ogura, Y Akutsu, S Motohashi, T Iizasa, H Endo, T Fujisawa, H Shinkai, M Taniguchi. 1999. Antitumor cytotoxicity mediated by ligand-activatedhuman Vα24 NKT cells. Cancer Res, 59(20):5102-5
Kim J, C K Chang, T Hayden, F C Liu, J Benjamin, A J Hamerman, L L Lanier,S M Kang. 2007. The activating immunoreceptor NKG2D and its ligands are involved in allograft transplant rejection. J Immunol, 179(10):6416-20
Kim E S,M S Kim,A Moon. 2005. Trans forming growth factor ( TGF)-beta in conjunction with H-ras activation promotes malignant progression of MCF10A breast epithelial cells. Cytokine, 9(2):84-91
Kim J,C K Chang,T Hayden, F C Liu, J Benjamin, J A Hamerman, L L Lanier, S M Kang. 2007. The activating immunoreceptor NKG2D and its ligands are involved in allograft transplant rejection. J Immunol, 179(10):6416-20
Kim R, M Emi, K Tanabe. 2007. Cancer immuno editing from immune surveillance to immune escape. Immunology, 121(1):1-14
Kirchner H H,P Anton,J Atzpodien. 1995. Adjuvant treatment of locally advanced renal cancer with autologous virus- modified tumor vaccines. World J Urol, 13(3): 171-3
Kirn D H,F McCormick. 1996.Replicating viruses as selective cancer therapeutics. Mol Med Today,2(12):519-57
Kitamura H,K Iwakabe,T Yahata,S Nishimura, A Ohta, Y Ohmi, M Sato, K Takeda, K Okumura, LV Kaer, T Kawano, M Taniguchi, T Nishimura. 1999. The natural killer T(NKT)cell ligand a-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med,189(7): 1121-8
Kitamura H,K Iwakabe ,T Yahata ,S Nishimura ,A Ohta ,Y Ohmi ,M Sato , K Takeda ,K Okumura, L Van Kaer, T Kawano, M Taniguchi, T Nishimura. 1999. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.J Exp Med, 189(7):1121-8
Klein J L,J D Roberts,M D George. 1999. Swainsonine protects both murine and human haematopoietic from chemotherapeutic toxicity.Br J Cancer,80(1~2):87-95
Knowles H,R Leek,A L Harris. 2004. Macrophage infiltration and angiogenesis in human malignancy. Novartis Found Syrup, 256:189- 200
Konishi J, K Yamazaki, H Yokouchi, N Shinagawa, K Iwabuchi, M Nishimura. 2004. The characteristics of human NKT cells in lung cancer-CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients. Hum Immunol,65(11): 1377-88
Kono K,H Kawaida, A Takahashi. 2006. CD4+CD25 high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers.Cancer Immunol Immunother, 55(9);1064-71
Kruger-Krasagakes S, K Krasagakis, C Garbe, E Schmitt, C Hüls, T Blankenstein,T Diamantstein. 1994. Expression of interleukin 10 in human melanoma. Br J Cancer,70(6):1182-5
Kubota T, Y Haramaki, Y Oki, F Saito, A Kuroshima, M Numata. 1988. Antitumor activity of vinegar made from pearl barley grains.Nippon Nogeikagaku Kaishi, 62(1):23-8
Kuo C C,M C Shih,Y H Kuo,W C Chiang. 2001. Antagonism of free-radical-induced damage of adlay seed and its antiproliferative effect in human histolytic lymphoma U937 monocytic cells. J. Agric. Food Chem. 49(3):1564-70
Lanier L L, B C Corliss, J Wu, C Leong, J H Phillips. 1998. Immunoreceptor DAP12 bearing atyrosine-based activation motif is involved in activating NK cells. Nature, 391(2):703-7
Lavergne E, C Combadiere, M Iga, A Boissonnas, O Bonduelle, M Maho, P Debré, B Combadiere. 2004. Intratumoral CC chemokine ligand 5 over expression delays tumor growth and increases tumor cell infiltration . J Immunol, 173(6):3755-62
Leon K, K Garcia, J Carneiro, A Lage. 2007. How Regulatory CD25+CD4+T Cells Impinge on Tumor Immunobiology:The Differential Response of Tumors to Therapies.J Immunol,179(9):5659-68
Le Q T, G Shi, H Cao, D W Nelson, Y Wang, E Y Chen, S Zhao, C Kong, D Richardson, K J O'Byrne, A J Giaccia, A C Koong. 2005. Galectin-1:a link bet ween tumor hypoxia and tumor immune privilege. J Clin Oncol, 23(35):8932- 41
Lewis C E, J W Pollard. 2006. Distinct role of macrophages in different tumor microenvironments. Cancer Res, 66(2):605-12
Liang W,H Wang, T M Sun. 2003. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract.World J Gastr oenterol, 9 (3):495-8
Li D P. 2004. General survey and progress in clinical trals abroad over Kanglaite injection. CJIM,10(3):233-5
Li D P, J M Huang, W A Su. 1999. Chemical composition of Coixseed's fat. Tradit Chin Drug Res Clin Pharm, 10(2):99-101
Liebrich W,P Schlag,M Manasterki. 1991. In vitro and clinical characterization of Newcastle disease-virus modified autologous tumor cell vaccine for treatment of colorectal cancer Patients. Eur J Cancer ,27(6):703-10
Li F Y, H R Chen. 2000. Experimental study on traditional Chinese medicine Coix seed’s effect on effect enhancing, toxic reducing to chemo therapeutic drug cisp lat in and mitomycin . Acta Chin Med Pharm, 2(28):44-45
Li X, D F Ye,X Xie, H Z Chen,W G Lu. 2005. Proportion of CD4+CD25 regulatory T cell is increased in the patients with ovarian carcinoma. Cancer Invest, 23(5):399-403
Li Y. 1998. Analysis of long term results of treatment for advance nasopharyngeal carcinoma by Coicis Semen combined wItradi otherapy . Acta Med Sin , 11(1):10-11
Ljunggren H G, K Kirre. 1990. In search of the“missing self”: MHC molecules and NK cell recognition . Immunol Today,11(7):237-44
Lomniczi B. 1975. Thermostability of Newcastle disease virus strains of different virulence.Arch.virol.,47(3):249-55
Lorence R M, P A Rood, K W Kelley. 1988. Newcastle disease virus as an antineoplastic agent :induction of tumor necrosis factor-a and augmentation of its cytotoxicity. J Natl Cancer Inst,80(16):1305-12
Lorence R M, B B Katubig,K W Reichard. 1994. Complete regression of human fibrosarcoma xenogearts after local Newcastle disease virus therapy.Cancer Res, 54(23):6017-21
Lorence R M,K W Reichard,B B Katubig. 1994. Complete regression of human neuroblastom xenografts in athymic mice after local Newcastle disease virus therapy.J Natl Cancer Ins, 86(16):1228-33
Lorence R M,K W Reichard,C J Cascino. 1992. transformation of human fibroblastsenhances cytotoxicity and rePlication by New-castle disease virus(ND V).Proc Am Assoc Cancer Res, 33:398
Eva L,C A Savary,R S Freedman.1984. Mtural killer cell cytotoxic potential of patients with ovariancarcinoma and its modulation with virusmodified tumor cell extract.Cancer Immunol Imunother,17(2):124-9
Loza M J, L Zamai, L Azzoni, E Rosati, B Perussia. 2002. Expression of type 1 (interferon gamma) and type 2 (interleukin-13 , interleukin-5) cytokines at distinct stage of natural killer cell differentiation from progenitorcells. Blood, 99(4):1273-81
Lutsiak M E C, Y Tagaya, A J Adams, J Schlom, H Sabzevari. 2008. Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells. J Immunol 180:5871-81
Lu Y, Z M Zhang, R H Zhang. 1999. The study on anti neoplastic effect of Coix seed oil . Pharm Clin Chin Mater Med, 15 (6):21-23
Mailliard R B, Y I Son, R Redlinger, P T Coates, A Giermasz, P A Morel, W J Storkus, P Kalinski. 2003. Dendritic cells mediate NK cell help for Th1 and CTL responses: Two signal requirement for induction of NK cell helper function. J Immunol, 171(5):2366-73
Mallmann P,A M Eis-Hubinger,D Krebs. 1992. Lymphokine- activated tumor- infiltrating lymphocytes and autologous tumor vaccine in breast and ovarian cancer. Onkologie, 15(6):490-6
Mantovani A, A Sica, S Sozzani, P Allavenab, A Vecchib, M Locatia. 2004. The chemokine system in diverse forms of macr ophage activation and polarization .Trends Immunol, 25(12):677-86
Smyth M J,E M Wallace, S L Nutt, H Yagita, D I Godfrey, Y Hayakawa. 2005. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer.J Exp Med, 201(12):1973-85
Turk M J, J A Guevara-Pati?o, G A Rizzuto, M E Engelhorn, A N Houghton. 2004. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.J Exp Med,200(6):771-82
Matsumura Y,S N Byrne,D X Nghiem, Y Miyahara, S E Ullrich. 2006. A role for inflammatory mediators in the induction of immunoregulatory B cells. JI mmunol, 177(19):4810-17
Matsushita N,S A Pilon-Thomas,L M Martin,A I Riker. 2008. Comparative methodologies of regulatory T cell depletion in a murine melanoma model .J Immunol Methods,333(1-2):167-79
Meadows S K,M Eriksson,A Barber,C L Sentman. 2006. Human NK cell IFN-γproduction is regulated by endogenous TGF-β. Int Immunopharmacol, 6(6):1020-8
Medana I M, A Gallimore, A Oxenius,MarianneM A Martinic, H Wekerle, H Neumann. 2000. MHC class I-restricted killing of neurons by virus-specific CD+8 T lymphocytes is effected through the Fas/FasL ,but not the perforin pathway.Eur J Immunol,30(12):3623-33
Metelitsa L S, O V Naidenko, A Kant,H W Wu, M J Loza, B Perussia, M Kronenberg, R C Seeger. 2001. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol, 167(6):3114-22
Metelitsa L S, K I Weinberg, P D Emanuel, R C Seeger. 2003. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia, 17(6):1068-77
Miller A M, K Lundberg, V Ozenci, A H Banham, M Hellstr?m, L Egevad, PPisa. 2006. CD4+CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol, 177(10):7398-405
Mittal S, N A Marshall, L Duncan, D J Culligan, R N Barker,M A Vickers. 2008. Loca landsyste micinduction of CD4+CD25+regulatory T-cell population by non-Hodgkin lymphoma. Blood,111(11):5359-70
Miwa N, S Hayakawa, S Miyazaki, S Myojo, Y Sasaki, M Sakai, O Takikawa, S Saito. 2005. IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferon- gamma increase in normal pregnancy but decrease in spontaneous abortion .Mol Hum Reprod, 11(12):865-70
Mocikat R, H Braumuller, A Gumy, Oliver Egeter, Heike Ziegler, Uwe Reusch, Anja Bubeck, Jacques Louis, Reinhard Mailhammer, Gert Riethmüller, Ulrich Koszinowski, Martin R?cken. 2003. Natural killer cells activated by MHCⅠ(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity, 19(4):561-9
Mohla S,S White, K Grzegorzewski. 1990. Inhibition of growth of subcutaneous xenografts and metastasis of human breast carcinoma by swainsonine: modulation of tumor cell HLA class I antigens and host immune effector mechanisms.Anticancer Res, 10(6):1515-22
Monach P A, H Schreiber, D A Rowley. 1993. CD4+ and B lymphocytes in transplantation immunity. II Augmented rejection of tumor allografts by mice lacking B cells. Transplantation,55(6):1356-61
Moodycliffe A M, D Nghiem, G Clydesdale, S E Ullrich. 2000. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol,1(6):521-5
Moretta A, C Bottino, M Vitale, D Pende, C Cantoni, M C Mingari, R Biassoni, L Moretta.2001. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Ann Rev Immunol,9(4):197-223
Mortier E,T Woo, R Advincula, S Gozalo, A Ma. 2008. IL-15Rαchaperones IL-15 to stable dendritic cellmembrane complexes that activate NK cells via trans presentation. J Exp Med, 205(5):1213-25
Moss D M. 2003. The many faces of macrophage activation. Journal of leukocyte biology, 73(2):209-12 Munn D H,M D Sharma,J R Lee,K G Jhaver, T S Johnson, D B Keskin, B Marshall, P Chandler, S J
Antonia, R Burgess, C L Slingluff Jr, A L Mellor. 2002. Potential regulatory function of human dendritic cells expressing indoleamine2,3-dioxygenase.Science, 297(5588):1867-70.
Munn D H, M D Sharma, A L Mellor. 2004. Ligation of B7-1/B7-2 by human CD4+T-cells triggers indoleamine2,3-dioxygenase activity in dendritic cells. J Immunol, 172(7):4100-10
Nagaraj S,K Gupta,V Pisarev, L Kinarsky, S Sherman, L Kang, D L Herber, J Schneck, D I Gabrilovich. 2007. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med, 13:828-35
Nagler A, L L Lanier,S Cwirla, J H Phillips. 1989. Comparative studies of human FcRIII 2 positive and negative natural killer cells. J Immunol , 143(10):3183-91
Guha-Thakurta N,A Jeannine ,Majde. 1997. Early induction of Proinflammatory cytokine and type I interferon mRNAs following lcwcastle disease virus,POLY(rI:rc),or lowdose LPS challenge of the mouse. JInterferonCytokine-Ies,17(4):197-204
Natarajan K,N Dimasi,J Wang, R A Mariuzza, D H Margulies. 2002. St ructure and function of natural killer cell receptors: Multiple molecular solutions to self, non-self discrimination. Annu Rev Immunol, 20(4):853-85
Nicholl M, A Lodge, I Brown, S L Sugg, J Shilyansky. 2004. Restored immune response to an MHC-II-Restricted antigen in tumor-bearing hosts after elimination of regulatory T cells. J Pediatr Surg, 39(6):941-6
Nicol A,M Nieda,Y Koezuka, S Porcelli, K Suzuki, K Tadokoro, S Durrant, T Juji. 2000. Human invariant Vα24+ natural killer T cells activated byα-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells.Immunology, 99(2):229-34
Nicol A,M Nieda,Y Koezuka. 2000. Human invariant V alpha24+ natural killer T cells activated byalpha-galactosylceramide(KRN7000) have cytoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells, 99(2): 229-34 Mach N, G Dranoff. 2000. Cytokine-secreting tumor cell vaccines. Current Opinion in Immunology, 12(5):571-5
Nieda M, M Okai, A Tazbirkova, H Lin, A Yamaura, K Ide, R Abraham, T Juji, D J Macfarlane, A J Nicol. 2004. Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood,103(2):383-9
Nomura T, S Sakaguchi. 2005. Naturally arising CD25+CD4+ regulatory T cells in tumor immunity. Microbiol Immunol, 293:287-302
Numata M,A Ammamoto,A Moribayashi. 1994. Antitumor components isolated from the Chinese herbal medicine Coix lachrymal-jobi. Planta Med,60(4):356-59
Oh H, H Takagi, A Otani, S Koyama, S Kemmochi, A Uemura, Y Honda. 2002. Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): A mechanism contributing to VEGF-induced angiogenesis.Proc Natl Acad Sci, 99(1):383-8
Ohm J E,D P Carbone. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res, 23(2-3):263-72
Ohta A, E Gorelik, S J Prasad, F Ronchese,D Lukashev,M K Wong, X Huang, S Caldwell, K Liu, P Smith, J F Chen,E K Jackson,S Apasov, M Sitkovsky. 2006. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci, 103(35):13132-7
Oladipe O A, P M Furbert-Harris, I Laniyan. 2003. Enhanced Proliferation of functionally comPetent bone marrow cell in different strains of mice treated with swainsonine.Int ImmunoPharmacology,3(3):445-55
Olden K, P Breton,Grzegorzewski, Y Yasuda. 1991. The potential importance of swainsonine in therapy for cancer immunology.Pharmacol Ther,50(3):285-90.
Ormandy L A, T Hillemann, H Wedemeyer, M P Manns, T F Greten, F Korangy. 2005. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res, 65(6):2457-64
Ostrand-Rosenberg S. 2004. Animal models of tumor immunity, immunotherapy and cancer vaccines.Cancer Immunol Immunother,532:86-91
Ostrand-Rosenberg S, J G Michael,K C Virginia. 2000. STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma.J Immunol,165:6015-6019
Pardali K, A Moustakas. 2007. Actions of TGF-βas tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta,1775(1):21-62
Park J Y, M Z Yang, H S Jun. 2003. Effect of raw brown rice and Job’s tear supplemented diet on seem and hepatic lipid concentrations ,antioxidative system ,and immune function of rats.J Korean Soc Food Sci Nutr,32(2):197-206
Peng G, Z Guo, Y Kiniwa, V Kuishin, W Y Peng, T H Fu, Y W Daniel, Y C Li, Y. W Helen, R F Wang. 2005. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science, 309(5739):1380-4
Peng Y, Y Laouar, M O Li, E A Green, R A Flavell . 2004. TGF-βregulates in vivo expansion of Foxp3-expressing CD4+ CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci, 101(13):4572-7
Perez N, S Karumuthil-Melethil, R B Li. 2008. Preferential Costimulation by CD80 Results in IL-10-Dependent TGF-{beta} 1+-Adaptive Regulatory T Cell Generation. J Immunol, 180:6566-76
Phan G Q, J C Yang, R MSherry, P H wu, S L Topalian, D J Schwartzentruber, N P Restifo, L R Haworth, C A Seipp, L J Freezer, K E Morton, S A Mavroukakis, P H Duray, S M Steinberg, J P Allison, T A Davis, S A Rosenberg. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.Proc Natl Acad Sci , 100(14): 8372-7
Phuangsab A, R M Lorenc,K W Reichard. 2001. Newcastle disease virus therapy of human tumorxenografts: antitumor effects of local or systemic administration.cancer Lett,172(1):27-36
Poggi A, A M Massaro, S Negrini, P Contini, M R Zocchi. 2005. Tumor-induced apoptosis of human IL-2-activated NK cells: role of natural cytotoxicity receptors. J Immunol, 174(5): 2653-60
Pollard J W. 2004. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer, 4 (1):71-8
Polverini P J. 1987. Effect of macrophage depletionon growth and neovasculatization of hamsterbuccal pouch carcinomas. J Oral Pathol, 16(9):436-41
Powell L D, S W Whiteheart, G W Hart. 1987. Cell surface sialic acid influence tumor cell recognition in the mixed lymPhocyte reaction. J Immunol ,139(1):262
Power S, R Thiele, G Staehler. 1995. Tumor vaccination in renal cell carcinoma with and without interleukin--2(IL-2) as adjuvant.A clinical contribution to the development of effective active specific immunization. Urolog A, 34(3):215-20
Puangs A B A, R M Lorence, K W Reichard. 2001. Newcastle disease virus therapy of human tumor xenografts: Antitumor effects of local or systemic administration. Cancer Lett, 172:27-36
Qin Z, Richter G, T Schuler, I Sabrina, X T Cao, B Thomas. 1998. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med, 4:627-30
Reichard K W,Lorence R M,Cascino C J.1992. Newcastle disease virus selectively kills human tumor cells .J Surg Res, 52(5): 448-453
Reichard K W,R M Lorence,C J Cascino. 1992. N-myc oncogene enhances the sensitivity of neuroblastoma to killing by Newcastle disease virus .Surg Forum,43 :603
Reichard K W,R M Lorence, B B Katubig. 1993. Retinoic acid enhances killing of neu- roblastoma cells by Newcastle disease virus.J Pediatr Surg, 28(10):1221-6
Rodriguez P C, D G Quiceno, J Zabaleta. 2004. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen - s pecific T - cell responses. Cancer Res, 64: 5839-49
Rodriguez P C, A H Zea, K S Culotta, J Zabaleta , J B Ochoa , A C Ocho. 2002. Regulation of T cell receptor CD3zeta chain expression by L-arginine. J BiolChem, 277(24): 21123-9
Rooprai H K, A Kandanearatchi, S L Maidment. 2001. Evaluation of the effects of swainsonine, captopril, tangeretin and nobiletin on the biological behaviour of brain tumour cell in vitro. NeuroPothol APPl Neurobiol,27(1):29-39
Rouas-Freiss N, P Moreau, C Menier. 2007. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol, 17(6):413-21
Ruggeri L, M Capanni, E Urbani, P Katia, D S Warren, T Antonella, P Sabrina, R Daniela, F Francesco, A Franco, F M Massimo, V Andrea. 2002. Effectiveness of donor natural killer cell alloreactivit y in mismatched hematopoietic transplants. Science, 295(3):2097-100
RuggeriL, A Mancusi, M Capanni, U Elena, C Alessandra, A Teresa, S Martin, P Daniela, P Katia, B Emanuela, T Fabiana, B Erika,A Franco, F M Massimo, V Andrea. 2007. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value .Blood, 110 (1):433-40
Ryan A E, F Shanahan, J O'Connell, A M Houston. 2006. Fas ligand promotes tumor immune evasion of colon cancer in vivo. Cell Cycle, 5(3):246-9
Salceda S, T Tang, M Kmet, M Andrei, G Malavika, M Roberto, W H Liu, P Glenn, P Jackie. 2005. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res, 306(1):128-41
Savage H E, R D Rossen, E M Hessh. 1986. Antibody development to viral and allogenic tumorcell-associated antigens in patients with malignant melanoma and ovarium carcinoma treated with lysates of virus-infected tumor cells. Cancer Res,46(4 Pt2):2127-33
Schild H, P Von Hoegen, V Schirrmacher. 1989. Moddification of tumor cells b5 a low dose of Newcastle disease virus.Ⅱ.Augmented tumor specific 7 cell response as a result of CD4 and cd8 immune T cell cooperation cancer immunol immunother,28(1):22
Schreiber R D. 2005. Cancer vaccines 2004 opening address: themolecular and cellular basis of cancer immunosurveillance and immuno editing. Cancer Immun, 5( Suppl):1
Schlag P, M Manasterki, T Geneth. 1992. Active specific immunotherapy wit Newcastle disease virus modified autologous tumor cells following resection of live metastasis in colorectal cancer. First evaluation of clinical resPonse of Phase II trial .Cancer Immunol Immunother,35(5):325-30
Schreiber R D. 2004. Cancer vaccines opening address : themolecular and cellular basis of cancer immunosurveillance and immuno editing . Cancer Immun, 5 ( Supp l 1):1-8
Schunscher U, L Bai, V Umansky. 2000. Newcastle virus activates materophages for anti- tumor activity. Int JOncol, 16(2):363
Schwarz R E,D C Wojciechowicz,A I Picon.1999.Wheatgerm agglutinin-mediated toxicity in pancreatic cancer cell.Br.J Cancer,80(11):1754-62
Seki S, Y Habu, T Kawanura, T Kazuyoshi, D Hiroshi, O Takashi, H Hoshio. 2000. The liver as a crucial organin the first line of host defense: the roles of Kupffer cells, natural killer (NK) cells and NK1.1 Ag+ T cells in T helper 1 immune responses. Immunol Rev, 174(1):35-46
Serafini P, S C De, I Marigo, C Sara, D Luigi, G Giovanna, Z Paola, B Vincenzo. 2004. Derangement of immune responses by myeloid suppress or cells. Cancer I mmunol I mmunother, 53(2):64-72
Sessa C, D F Braud, A Perotti, B Jean, C Giuseppe, N Cristina, Z Flavia, G Luca, M Silvia, J José, D T Maurizio, Elisa Dall’ó, C Nicoletta. 2005. Trabectedin for women with ovarian carcinoma after treatmentwith platinum and taxanes fails. J Clin Oncol, 23(9):1867-74.
Shankaran V, H I keda, A T Bruce,J M White, E S Paul, J O Lloyd, D S Robert. 2001. IFN-γlymphocytes prevent primary tumour development and shape tumour immunogenicity . Nature, 410(6832)1107-11
Schirrmacher V, L Bai, V Umansky. 2000. Newcastle virus activates macrophages for anti-tumo activity. Int J Oncol, 16 (2):363-73
Schirrmacher V, A Griesbach, T Ahlertn. 2001. Antitumor effects of Newcastle Disease Virus in vivo:local versus systemic effect s.Int J Oncol,18(5):945-52
Schirrmacher V, C Haas, R Bonifer. 1997. Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface biding but not infection.Clin Cancer Res,3 (7):1135-48
Schirrm acher V,C Haas,R Bonifer. 1999. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory proper ties when using Newcastle disease virus.Gene Ther,6(1) : 63-73
Schirrmacher V, K Jurianz, C Roth. 1999. Tumor stimulator cell modification by infection with Newcastle disease virus :analysis of effects and mechanism in MLTC-CML culture. Int J Oncol,14(2):205-15
Shi F D, L V Kaer. 2006. Recip rocal regulation between natural killer cells and autoreactive T cells. Nat Rev Immunol, 6(10):751-60
Shih C K, W C Chiang, M L Kuo. 2004. Effects of adlay on azoxymethane-induced colon carcinogenesis in rats.Food Chem T oxicol, 42(8): 1339-47
Shi L,S Mai, S SIsrael, B Kylie, A T Joseph, H G Arnold. 1997. Granzyme B autonomously crosses the cell membrane and perforin initiates apoptosis and granzyme B nuclear localization.J Exp Med,185(5):855-66
Shi ZY, T X Li, Q P Wang. 2001. Applied study of Coicis Semen injection combined with chemoembo lization on midle and advanced stage liver cancer. Tumor, 21(3):233-4
Sica G L, I H Choi, G Zhu, T Koji, S D Wang, T Hideto, I C Andrei,B F Dallas, B Jürgen, L P Chen. 2003. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. I mmunity, 18(6):849-61
Smyth M J,N Y Crowe, Y Hayakawa, T Kazuyoshi, Y Hideo, I G Dale. 2002. NKT cells-conductors of tumor immunity. Curr Opin Immunol,14(2):165-71
Smyth M J, K Y Thia, S E Street, C Erika, A T Joseph, T Masaru, K Tetsu,B P Sonja, Y C Nadine, I G Dale. 2000. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med, 191(4):661-8
Smyth M J, M E Wallace, S L Nutt, Y Hideo, I G Dale, H Yoshihiro. 2005. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med, 201(12):1973-85
Sopit W, B Chanchai, K Supranee. 2001. Serum total sialiacid in cholangiocarcinoma patients : An ROC curve analysis . Clinical Biochemistry, 34 (7) : 537-41
Sredni B, M Weil, G Khomenok, L Ilana, T Seagal, Yael Mardor Zvi Ram , O Arie, K Amir, M Shalom, I C Yan, H Zvi. Rappaport ,F Ilya, A Michael, L L Dan, K Yona. 2004. Ammonium trichloro ( dioxoethylene-o,o’) tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res, 64 (5):1843-52
Steidl C, T Lee, S P Shah, F Pedro, G M Han, N Tarun, D Allen, S J Jones, I Javeed, D W Dennis, A B Martin, R Andreas, M H Hans-Konrad, M R Lisa, C Elias, D Jan, M Rita, R C James, R T Ray, E S Jaffe, LGeorg, M C Joseph, L M Staudt, W C Chan, R D Gascoyne. 2010. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med, 362(10):875-85
Steinbrink K, H Jonuleit, G Muller. 1999. Interleukin - 10 - treated human dendritic cells induce a melanoma - antigen - s pecificanergy in CD8 ( + ) T cells resulting in a failure to lyse tumor cells. Bl ood, 93:1634-42
Steock M, C Marland-Noske, M Manasterki. 1993. In vitro expansion and analysis of lymphocyte microcultures obtained from active specific immunization with autologou Newcastal disease virus modified tumor cells.Cancer Immunol Immunnother, 37(4):240-4
Takahashi T,K Haraguchi, S Chiba, Y Masaki, S Yoichi, H Hisamaru. 2003. Va 24+ natural killer T-cell responses against T-acute lymphoblastic leukaemia cells: implications for immunotherapy. Br J Haematol, 122(2): 231-9
Takahashi A, K Kono, J Itakura, H Amemiya, H Iizuka, H Fujii, Y Matsumoto. 2002. Correlation of vascular endothelial growth factor–c expression with tumor - infiltrating dendritic cells in gastric cancer. Oncol ogy, 62(2):121-7
Takeda K, Y Hayakawa, M Atsuta, H Seokmann, V K Luc, K Kimio, I Mamoru, Y Hideo, K Okumura. 2000. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. Int Immunol,12(6):909-14
Taniguchi M, M Harada , S Kojo , T Nakayama , H Wakao . 2003. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol,21:483-513
Tanimura A. 1961. Studies on the ant-itumor component in the seeds of Coix lachryma-jobi Lvar ma-yuen (Roman) Stapef II .Isolation and antitumor activity of coixenolide.Chem Pharm Bull,9(21):47-53
Tan YT, C Y Wei, T Li. 2001. Study on influence of immuno logic function of patients with primary hepatocarcinoma by totalext racts of Coix seed injection. Chin J Prev Treat, 8 (1):22-5
Terabe M, S Matsui, N T Nancy, H J Chen, C Watson, D D Donaldson, P C David, E P William,J A Berzofsky.2000. NKT cell-mediated repression of tumor immunosurveillanceby IL-13 and the IL-4R-STAT6 pathway.Nat Immunol,1(6):515-20
Terabe M,J M Park,J A Berzofsky. 2004. Role of IL-13 in regulation of anti-tumor immunity and tumor growth .Cancer Immunol,53(2):79-85
Terabe M, S Matsui, N Noben-Trauth, H J Chen, C Watson, D D Donaldson, D P Carbone, E P William,J A Berzofsky. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol, 1(6):515-20
Termeer C C, Schirrmacherv,E B Bmeker. 2000. Newcastle disease virus infection induces B7-1/B7-2-Independent T-cell activity in human melanoma cells.Cancer Gene Ther,7(2):316
Thorsten H, C R Stephen, S Matthia,LorenzT, B C FrancesR. 2004. Enhanced invasiveness of breast cancer cell lines upon cocultivation with macrophages is due to TNF-αdependent up-regulation of matrix metalloprotease. Carcinogenesis, 25(8):1543-9
Tokuda H, T Matsumoto , T Konoshima. 1990. Inhibitory effect on Epstein-Barr virus activation and anti-tumor promoting activities of Coix seed . Planta Medica, 56(6):653-54
Turk M J, J A Guevara-Patino, G A Rizzuto, E E Manuel, N H Alan. 2004. Concomitant tumor immunity to apoorly immunogenicmelanoma is prevented by regulatory T cells. J Exp Med, 200(6):771-82
Tyler J Curiel, C George, Z Linhua, A Xavier, P Cheng, M Peter,E H Melina, J R Conejo-Garcia, LZhang, B Matthew, Y Zhu, SH Wei, Ilona Kryczek, D Ben, G Alan, M Leann, L Andrew, L D Mary, K L Knutson, L Chen, W P Zou. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 10:942-9.
Tzadok-David Y,M Metzkin-Eizenberg,Z Zakay-Rones.1995. The effect of a mesogenic and lentogenic Newcastle disease virus strain on Burkitt lymphoma Daudi cells. J Cancer Res Clin Oncol, 121(3):169-74
Tzong-Tyng H, H Wang, E A Kingsley, G P Risbridger, P J Russell.2008. Molecular profiling of bladder cancer involvement of the TGF-beta pathway in bladder cancer progression . Cancer Lett , 265(1): 27-38
Ukita C, A Tanimura. 1961. Studies on the antitumor component in the seeds of Coix lachrymal-jobi variety ma-yuen . Isolation and anti-tumor activity of coixenolide.Chem Pharm Bull, 9(1):43-46
Umansky V, V A Shatrov, V Lehmann,S Volker . 1996. Induction of NO synthesis in macrophages by Newcastle disease virus is associated withactivation of nuclear factor-κB.Int Immunol, 8(4):491-8
Umer I, T Chaudhry, K Peter. 2006. Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-γand inhibit Tumor Growth . Cancer Research, 1(66): 10497- 10504
Varla Leftherioti M. 2004. Role of a KIRSP HLA2 C allorecognition-system in pregnancy. J Reprod Immunol, 62 (122) : 19-27
Voss S D, J Daley, J Ritz, J R Michael. 1998. Participation of the CD94 receptor complex in costimulation of human natural killer cells . J Immunol, 160(2):1618-26
Wang H, X Xie, WG Lu, D F Ye, H Z Chen, X Li, Q Cheng. 2004.Ovarian carcinoma cells inhibit T cell proliferation: suppression of IL-2 receptor beta and gamma expression and their JAK -STAT signaling pathway. Life Sci,74 (14):1739-49
Wang H Y, D A Lee,G Peng, Z Guo ,Y Li ,Y Kiniwa ,E M Shevach , R F Wang .2004. Tumor - specific human CD4 + regulatory T cells and their ligands : implications for i mmunotherapy. Immunity, 20(1):107-18
Wang L Y,N Azad,L Kongkaneramit, F Chen, Y Lu, B H Jiang, R Yon. 2008. The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation. J Immunol,180:3072-80
Wei C Y, D P Tang , K Tang. 2000. Experimental study on cyto toxicity of cell of primary hepatocarcinoma by to talext racts of Coix seed injection . Chin J Prev Treat, 7 (6) : 609-13
White S L, T Nagai, S K Akiyama. 1991. Swainsonine stimulation of the proliferation and colony forming activity of murine bon marrow.Cancer Commun,3:83-91.
Wittke F, R Hoffmann, J Buer. 1999. Interleukin 10 (IL-10):an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br J Cancer,79:1182 - 4
Wyckof J, W G Wang, E Y Lin, Y Wang, P Flona, E R Stanley, G Thomas, W Jeffrey, Pollard, S Jeffrey, C John. 2004. A paracrineloop between tumor cells and macromphages is required for tumor cellmigration in mammary tumors. Cancer Res, 64 (19): 7022– 9
Yang Y. 2003. Generation of major histocompatibility complex class I antigens. Microbes Infect,5(1):39-47
Yang Y, J Ochando,A Yopp, B S Jonathan, Y Z Ding. 2005. IL-6 plays a unique role ininitiating c-Maf expression during early stage of CD4 T cell activation. J I mmunol, 174(5):2720-9
Yang Y,J H Paik,Cho D,J A Cho,C W Kim. 2008. Resveratrol induces the suppression of tumor-derived CD4 +CD25+regulatory Tcells.Int Immunopharmacol ,8(4):542-7
Yang Z Z,A J Novak,M J Stenson. 2006. Intratumoral CD4 +CD25 +regulatory T -cell - mediated suppression of infiltrating CD4 +T -cells in B - cell non - Hodgkin lymphoma . Blood,107:3639- 46
Yewdell J W. 2003. Immunology hide and seek in the peptidome. Science, 301(5638):1334-5
Yoon S R,J W Chung,I Choi. 2007. Devel opment of natural killer cells from hematopoietic stem cells. Mol Cells, 24(1):1-8
Young N T, M Uhrberg. 2002. KIR expression shape cytotoxic repertoires :a development alprogram of survial. TRENDS in immunology, 23(2):71-5
Young J C,Y L Sook. 2005. Cytotojcity and Multidrug-Resistance Reversing Activity of Extracts from Gamma-Irradiated Coix lachrymal-jobii. Var ma-yuen Stapf Seed. J Korean Soc Food Sci Nutr,34(5):613-18
Zamai L, C Ponti,P Mirandola, G Giuliana, P Stefano, G Laura, C Lucio,V Marco. 2007. NK cells and cancer. J Immunol, 178(7):4011-16
Zang X, P Loke,J Kim,K Murphy,R Waitz,P J Allison.2003.B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad SciUSA,100(18):10388-92
Zea A H, P C Rodriguez, M B Atkins, C Hernandez, S Signoretti, J Zabaleta, D McDermott, D Quiceno, A Youmans, A O’Neil, J Mier, C A Ochoa.2005.Arginase - producing myeloid suppressor cells in renal cell carcinoma patients : amechanism of tumor evasion. Cancer Res, 65(15):3044-8
Zeis M, L Uharek, B Glass, J Steinmann, P Dreger, W Gassmann, N Schmitz. 1997. Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukaemia effect in mice. Br J Haematol, 96(4):757-61
Zeng J, P Fournier, V Schirrmader. 2002. Induction of interferon alpha and tumor necrosis factor-related apoptosis inducing ligand in human blood mononuclear cells by hemagglutinin2 neuraminidase but not F protein of Newcastle disease virus. Virology, 297 (1):19-30 .
Zhang J G, G Liu, J H Liu. 2003. Advanced pancreatic cance treated with Coicis Semen injection combined with 52 Fluorouracil and cisp lat in .Tumor (肿瘤) ,23(4) : 347
Zhang J M, J S Yang, Y J Zhao. 2002. Progress report in chemical constituents and pharmacological activities of Coix. Chin Pharm J, 37(1):82-111
Zhang J G, G S Xu. 2007. Suppression of FasL expression in tumor cells and preventing tumor necrosis factoreinduced apoptosis by adenovirus 14.7K is an effective escape mechanism for immune cells. Cancer Genetics and Cytogenetics ,179:112-7
Zha Y, C Blank, T F Gajewski. 2004. Negative regulation of T -cell function by PD– 1. Crit Rev I mmunol, 24:229-37
Zheng Y, Z Cai, S Wang, X Zhang, J Qian, S Hong, H Li, M Wang, J Yang, Q Yi. 2009. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug - induced apoptosis . Blood, 114 (17) : 3625-8
Zhou G, Z Lu, J D McCadden, H I Levitsky, A L Marson. 2004. Reciprocal changes in tumor antigenicity and antigen- specific T cell function during tumor progression. J Exp Med, 200(12):1581-92
Zhou S H, R Ou, L Huang,M Demetrius.2002.Critical role for perforinr,Fas/FasL2, and TNFR1-mediated cytotoxic pathways in down-regulation of antigen-specific T cells during persistent viralinfection. J Virol, 76(2):829-40
Zhu Q, J Y Liu, HW Xu, C M Yang, AZ Zhang, Y Cui, H B Wang. 2005. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system. World J Gast roenterol,11 (39):6125-9
Zorn U, I Dallmann, J Grosse. 1994. Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus .Cancer Biother, 9 (3):225-35
Zorn U, S Dnensing, F Langkopf. 1997. Active specific immunotherapy of renal cell carcinoma:cellular and humoral immune response. Cancer Biother RadioPharm, 12 (3):157-65
白莲花,钱振超.1994.新城鸡瘟病毒激活的巨噬细胞抗肿瘤转移作用的研究.上海免疫学杂志,14(6):334-6
白莲花,于春,鲍秋莉,顾芳,李娟,陈乃玲,钱振超.1997.新城鸡瘟病毒诱导人外周血单核细胞产生的一氧化氮与细胞毒依赖作用的研究.中国肿瘤生物治疗杂志,4(3):184-5
鲍英,夏璐,姜华,张学军,袁耀宗.2004.康莱特诱导人胰腺癌细胞凋亡的实验研究.上海医学,27(6):421-4
鲍英,夏璐,姜华,章永平,乔敏敏,张学军,袁耀宗.2005.薏苡仁提取液对人胰腺癌细胞凋亡和超微结构的影响.胃肠病学,10(2):75-8
蔡宝祥.2002.家畜传染病学.北京:中国农业出版社,307
崔成旭,李峻岭,郝学志,王金万,李玉升,屈风莲,赵龙妹,储大同.1998.康莱特联合化疗治疗晚期非小细胞肺癌8例临床观察.实用肿瘤杂志,13(6):376-7
戴淑琴,王军业,马国伟,戎铁华,王欣,林鹏,叶文峰,张兰军,李小东,张旭,姚广裕.2006.康莱特注射液对现代二野清扫术食管癌患者围手术期细胞免疫支持治疗的临床随机对照研究.实用肿瘤杂志,21(6):515-8
董西林,王雅娟.1994.肝癌患者外周血T细胞亚群及免疫细胞活性研究.西安医科大学学报,120(4):474-475,494
龚非力,熊思东.2003.医学免疫学.科学出版社.109-13
古长庆,金宁一.鸡新城疫病毒抗肿瘤作及其机制的研究进展.2000.中国肿瘤生物治疗杂志,7(3):238-240
管国芳,金春顺,金宁一,米志强,李霄,连海,孙丽丽,文连姬,2005.新城疫病毒对Hep-2肿瘤细胞的抑制效应.中国耳鼻咽喉头颈外科,12(8):487-90
管国芳,金春顺,金宁一,张静敏.米志强,李霄,连海,孙丽丽,文连姬,崔葳.2005.新城疫病毒致Hep- 2肿瘤细胞死亡方式的研究.中国生物制品学杂志,18(6):461-4
郭坤元,梅家转,姚开泰.2007.人鼻咽癌细胞株CNE2对NK细胞KIR/NKG2D受体免疫编辑作用及其对NK细胞杀伤功能的影响.南方医科大学学报,27(3):247-9
郭坤元,梅家转,姚开泰,吟晓林.2007.NK细胞免疫编辑后的人鼻咽癌细胞株CNE2 HLAⅠ类分子和MICA/MICB的表达及其对NK细胞杀伤活性的影响.第四军医大学学报,28(11):1005-7
郭坤元,梅家转,姚开泰,尹晓林.2007.NK细胞免疫编辑后的人鼻咽癌细胞株CNE2HLAⅠ类分子和MICA/MICB的表达及其对NK细胞杀伤活性的影响.第四军医大学学报,28(11):996-8
郝光荣.1999.实验动物学.陕西人民卫生出版社,76
侯冰宗,李绵,刘泓基,志伟.1999.康莱特对晚期大肠癌患者NK细胞活性、sIL-2R、TNF-α影响的研究.实用肿瘤杂志,14(6):382-83
胡建兵,翁洁,刘颂莲.2003.康莱特联合介入化疗栓塞治疗中晚期肝癌疗效观察.陕西肿瘤医学,11(1):48-49
黄挺,陈震,杨雪飞,李勇,张志娣,黄伶,张建刚,张晓丽.2008.康莱特注射液抗恶性肿瘤肝转移疗效及机制的实验研究.中国现代应用药学杂志,25(1):13-15.
姜晓玲,张良,郭成.2000.康莱特注射液对血管生成的影响.肿瘤杂志,20(4):313-314
蒋晓山.1991.NDV-沙榄香烯瘤苗的临床应用及免疫效果的近期评价(附8例报告).大连医学院学报13(4):1-4
李炳生,陈秀华,任文龙,陆宏祺,姚玉龙,严惠芳.1998.康莱特注射液的抗肿瘤作用.中国医药工业杂志,29(10):456-8
李大鹏.2001.康莱特注射液抗癌作用机理研究进展.中国新药与临床药理,12(2):122-4
李健强,李六金.1991.兽医微生物学实验实习指导.陕西:陕西科学技术出版社.
李同度,刘爱国.1999.康莱特注射液控制癌痛及提高晚期癌症患者生存质量III期临床研究.中国肿瘤临床,26(5):372-6
李同度,刘爱国.1998.康莱特抗癌症恶病质实验研究.中国肿瘤临床,25(2):131-3
李学,吴晓秀,李佩文.1999.康莱特注射液治疗原发性肝癌的临床研究.中国肿瘤临床,26(6):475-6
李瑛.2002.康莱特诱导肿瘤细胞凋亡的实验研究.中国肿瘤临床,40(12):37-41
李瑛,焦顺昌,孙胜杰,魏秀芳.2005.康莱特注射液与泰素帝合用对肺癌细胞的增敏作用研究.中药新药与临床药理,16(6):424-6
李瑛,石廷章.2002.康莱特诱导肿瘤细胞凋亡的实验研究.中国肿瘤临床,29(12):869-73
李瑛,石廷章,魏秀芳.2001.康莱特诱导HL60细胞凋亡的实验研究.实用癌症杂志,16(1):9-10
梁铁军,秦成勇,谭艳蓉,蒋莹,赵小栖.2006.康莱特抑制肝癌细胞HepG2增殖的实验研究.中国肿瘤临床,33(13):23-6
梁智勇,王文泽,高洁,刘彤华.2006.康莱特注射液合并健择对移植于裸鼠的人胰腺癌的疗效初步研究.中华肿瘤防治杂志,13(3):177-80
刘剑仑,埃高莫·比佐,韦长元,唐东平,李挺.2001.康莱特注射液诱导人肝癌细胞凋亡的研究.实用癌症杂志,16(4):343-7
刘科耀,胡龄鹤,曾书标.1994.新城疫苗对鼻咽癌疗效的初步实验研究.耳鼻咽喉一头颈外科,1(3):171-173
刘炳亚,林言箴,尹浩然.1998.苦马豆素抑制胃癌生长及转移的实验研究.中华肿瘤杂志,20(5):168-70
刘苗生,王崇宇. 2006.康莱特增强中晚期食管癌患者对放疗的耐受性.现代肿瘤医学,14(5):566-67
刘名光,邝国乾,岳惠芬,等.1995.新城疫病毒IV系疫苗抗小鼠移植瘤作用的实验研究.广西医科大学学报,12(2):197
刘名光,邝国乾,岳惠芬,梁新强.1995.新城疫病毒La Sota株疫苗免疫治疗小鼠移植瘤的生存期观察.医学文选,16(2):112-3
刘名光,邝国乾,黎福祥,黄菊,张奕敬,岳惠芬,梁新强,杨南武,崔英.2000.新城病毒疫苗吸入接种效应及其对鼻咽癌患者的辅助疗效观察.癌症,19(10):912-5
刘名光,梁新强.2001.新城疫病毒诱导的抗体反应与肿瘤生长的相关分析.14(2):72-4
卢志平,罗和生,张法灿.2007.康莱特注射液联合三维适形放疗治疗中晚期肝癌.中国医学文摘老年医学,16(1):40-43.
罗荣辉,刘婉华,刁振琦,陈香才,张丽.2001.光动力疗法对肝癌小鼠的抗肿瘤及免疫效应研究.应用激光,21(3):211-13
梅家转,周健,郭坤元,魏红梅.2006.低表达MICA/MICB导致NK细胞对人鼻咽癌多药耐药细胞(CNE2/DDP)杀伤活性下降.中国肿瘤生物治疗杂志,13(5):349- 52
梅家转,郭坤元,吴远彬,周健,魏红梅.2007.同种异体NK细胞对人多药耐药鼻咽癌细胞裸鼠皮下移植瘤的抑制作用.中国肿瘤生物治疗杂志,14(3):249- 53
米志强,金宁一,龚伟.2003.pVVP3和pVHN核酸疫苗的构建、表达及对肿瘤细胞的作用.中国生物化学与分子生物学报,19(6):704-8
潘李珍.1997.新城疫弱病毒对人肺腺癌细胞系A549多细胞球体的作用.首都医科大学学报,18(3):209-13.
彭晓赤,缪荣金.2006.康莱特注射液对晚期癌症患者生存质量的影响.癌症进展杂志,4(3):263-65
朴炳奎,李佩文,吴良村,等.1998.康莱特注射液治疗原发性支气管肺癌III期临床总结/李大鹏.康莱特抗肿瘤的研究论文集.浙江浙江大学出版社,152-68.
钱明山,张才良.1998.康莱特注射液介人治疗原发性肝癌和原发性肺癌的临床研究/李大鹏康莱特抗肿瘤的研究论文集.浙江浙江大学出版社,214-29
山长平,杨秀芹,崔巍,郭恒照.2007.康莱特注射液联合小剂量化疗治疗晚期胰腺癌的临床观察.中药新药与临床药理,18(1):72-73
单虎,郭鑫,1998.新城疫病毒在鸡胚不同组织增殖的研究.中国畜禽传传染病20(3):144-6
单虎,王述柏,郭鑫,等.1998.新城疫病毒在鸡胚同组织增殖的研究.中国畜禽传染病,20(3):144-46
沈顺华,尹思源,吴汉林.2006.康莱特对大肠癌HT-29细胞株体外生长抑制作用的研究.实用肿瘤杂志,21(6):531-33
申文江,温昭信,沙永慧.1998.康莱特注射液联合放射治疗恶性肿瘤临床研究/李大鹏康莱特抗肿瘤的研究论文集.浙江浙江大学出版社,198-203
沈霞芬.2001.动物组织学与胚胎学.中国农业出版社.
石星,丁乾,王晶.2006.康莱特注射液联合化疗治疗晚期消化道肿瘤.中国中西医结合消化杂志,14(4):249-51
苏雁欣,陈英淮,康向华,李树祥.2000.新城疫病毒疫苗对小鼠S180肉瘤抑瘤作用的实验研究.34(1):15-17
孙丽亚,张立新,张立敏,李春海.1999.康莱特注射乳剂对MUC1粘蛋白表达的影响及其生物学意义.实用肿瘤杂志,14(6):380-2
唐省三,马亚珍.2004.新城疫病毒体内外抗肿瘤作用的研究.陕西医学杂志,33(12):1093-5
唐省三,马亚珍.2005.新城疫病毒对体外培养人膀胱癌EJ细胞凋亡机制研究作用.陕西医学杂志,34(5):521-4
陶厚权.1997.抗癌药Swainsonine的基础与临床研究进展.国外医药-合成药、生化药、制剂分册,18(1):34-36
陶厚权.1996.抗癌药Swainsonine的实验与临床研究进展.中国肿瘤临床,23(11):822-4
田玉山,贾维真.1989.组织学技术.陕西:西北农业大学.
王俊杰,孙新臣,申文江,俞莉章,于世平.1999.康菜特注射液诱发肾癌细胞凋亡及P53,bal-2表达的研究.中国肿瘤临床,26(6):439-42
王秀荣,王秀英,冯惠东.2005.白细胞介素-15协同新城疫病毒HN基因抗肿瘤免疫的作用.四川大学学报,36(2):284-5
王越华,李兆元,龚先奇.2006.康莱特注射液联合化疗治疗晚期结直肠癌.肿瘤,26(12):1137-8
王兆太,董光龙,王为忠.2002.康莱特注射液对胃癌患者细胞凋亡增殖及T细胞亚群的影响.细胞与分子免疫学杂志,18(5):463-5
魏林,戴建新,傅传刚.2001.新城疫病毒HN基因对肿瘤抗原诱导的抗肿瘤免疫的增强作用.中华微生物学和免疫学杂志,2l(6):619-22
魏林,戴建新,孙树汉.2000.新城疫病毒HN基因真核表达质粒的构建及其抗肿瘤作用的初步研究.第二军医大学学报,21(6):515-8
薛立娟,龚伟,葛涛,王宏伟,罗琴芳,孙大辉,李萍,金宁一.2002.新城疫病毒plRHN核酸疫苗构建和表达及对肿瘤细胞的影响.中国免疫学杂志,18(5):338-40
薛立娟,金宁一,龚伟,王宏伟,孙大辉,罗琴芳,葛涛,李萍.2003.新城疫病毒对肿瘤细胞生物学行为的影响.细胞与分子免疫学杂志.19(1):29-34
杨汉春,姚火春,王君伟,等.2003.动物免疫学.中国农业大学出版社,66-94
杨骅,王平,郑树.1998.康莱特抗肿瘤的研究论文集.浙江大学出版社,110-14
杨骅,王仙平,郑树,等.1998.康菜特抗肿瘤的研究论文集.浙江大学出艋社,115-18
杨骅,王仙平,郑树.1998.康莱特抗肿瘤的研究论立集.浙江大学出版社,107-9
杨惠玲,潘景轩,吴伟康.2000.高级病理生理学.科学出版社,:354-453,482-498
杨鸣琦.1997.豆类丝核菌苦马豆素提取及其抗肿瘤作用初步研究.陕西杨凌:西北农林科技大学
杨鸣琦,曹光荣.1997.苦马豆素的毒性、代谢与用途.动物医学进展,18(4):20-25
杨鸣琦,张黎,周宏超,路宏朝,黄增荣.2003.豆类丝核菌次级代谢产物抗肿瘤作用的病理学观察.西北农业学报,12(4):5-7
杨鸣琦,张黎,周宏超,黄增荣,路宏朝.2003.豆类丝核菌次级代谢产物的抑瘤作用及其对荷瘤小鼠巨噬细胞活性的影响.西北农林科技大学学报(自然科学版),31(Z1):55-8
杨志刚,曾耀英,何贤辉,王青,江逊.2004.NK细胞对小鼠异基因骨髓移植造血及免疫重建的影响. 中华血液学杂志,25(12):713-6
杨志刚,曾耀英,何贤辉,王通,王青.2004.NK细胞在小鼠异基因骨髓移植中的作用.中国病理生理杂志,20(9):1563-7
殷震,刘景华.1997.动物病毒学.第2版.北京:科学技术出版社,736-67
殷震,刘景华.1985.动物病毒学.北京科学出版社,674
姚莉,姚冬青.2007.康莱特改善晚期癌症患者生存质量的临床研究.中国药师,10(1):33-5
姚淑莲,成涛,宁亚利.2006.康莱特注射液改善老年晚期消化道肿瘤的临床症状分析.肿瘤,26(4):387-8
姚玉龙,陈秀华,任文龙,卢艳萍,戴静芝,李炳生.2002.康莱特软胶囊对小鼠的免疫促进作用研究.中药新药与临床药理,13(4):233-5
岳惠芬,邝国乾,刘名光,梁新强,黄菊,杨甫武.2000.IV型鸡新城疫苗升高恶肿病人白血球水平作用的研究.广西医学,22(1):22-3.
张爱琴,马胜林,孙在典,包素珍.2007.康莱特注射液对Lewis肺癌小鼠免疫功能的影响.浙江中西医结合杂志,17(4):199-200
张海青,李世业,付瑜,杨声,富延海,秦明,吕福东,闫东杰.等.1999.康莱特注射液治疗原发性肺癌的临床及病理学观察.中国肿瘤临床,26(6):477-8
张宏宇,白莲花,刘学仁.1995.新城鸡瘟病毒修饰的同种肿瘤细胞对肿瘤转移免疫防治效应.中华微生物学和免疫学杂志,15(1):19
张黎,杨鸣琦,黄增荣,路宏朝.2004.豆类丝核菌次级代谢产物对荷瘤小鼠T淋巴细胞活性的影响.军医进修学院学报,25(2):164-6
张萍,付兴华,彭军,马立人.2006.新城疫病毒诱导人自然杀伤细胞杀伤喉癌细胞株Hep-2的体外研究.中国现代医学杂志,16(4):512-5
张琪.2010.NDV弱毒苗与SW或polyiC联用对小白鼠移植性肿瘤S37的抑制作用研究,西北农林科技大学学报自然科学版,25(9):34-9
张守信,曹光荣,李绍君.1992.甘肃棘豆醇提物对小鼠移植性肿瘤S37、H22的抑制试验.畜牧兽医杂志,2:13-15.
中国科学院南京土壤研究所编著.1985.土壤微生物研究方法.科学出版社
张铁英,褚敏,倪志强,张扬.2007.康莱特可有效提高晚期恶性肿瘤患者的生存质量.实用肿瘤杂志,22(6):540-41
郑毛根,赵艾君,陈志全.2006.康莱特联合放疗对75岁以上未手术的老年食管癌患者安全性与疗效的评价.中国老年杂志,8(26):1127-8
A Asada T.1997.Treatment of human cancer with mumPs virus.Cancer34 (6):1907-28.
Aharinejad S,D Abraham ,P Paulus ,H Abri ,M Hofmann ,K Grossschmidt , R Sch?fer ,E R Stanley ,R Hofbauer. 2002.Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xengraft in mice. Cance Res, 62(18):5317-24.
Ahlert T, W Sauerbrei, G Bastert. 1997. Tumor cell number and viability as quality and efficacy parameters of autologous virus modified cancer vac2 cines in patients with breast or ovarian cancer.J Clin Oncol,15(7):2763
Ahmadzadeh M, S A Rosenberg. 2005.TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells.J Immunol,174(9):5215-23.
Alessandro P, R Z Maria.2006. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. Arch I mmunol Ther Exp, 54(5):323-33
Andre P, O Spertini, S Guia, P Rihet, F D Gerorge, H Brailly, J Sampol, P J Anderson, E Vivier. 2000. Modification of P-selectin glycolprotein ligand21 with natural killer cell-restricted sulfated lactosamine creates an alternate ligand for L2 selectin. Proc Natl Acad Sci USA ,97(7):3400-5
Aptsiauri N, T Cabrera,R Mendez, A Garcia-Lor, F Ruiz-Cabello, F Garrido. 2007. Role of altered expression of HLA class Imolecules in cancer progression. Adv Exp Med Biol, 601(4):123-31
AsadaT.1974.Treatment of human cancer with mumps virus.Cancer,34(6):1907-28
Asai O,D L Longo,Z G Tian,R L Hornung ,D D Taub ,F W Ruscetti ,W J Murphy . 1998.Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow t ransplantation. J Clin Invest, 101(9):1835-42
Bacchetta R,C Sartirana,M K Levings,C Bordignon, S Narula,M G Roncarolo.2002. Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur J Immunol,32(8):2237-45.
Bamusheng. 1989. Anti tumor and anti inflammation effects of Coix seed .World Med: Phytomed, 4(2):75-77
Bar-EliN,H Giloh,M Schlesinger.1996. Preferential cytotoxic ef fect of Newcastle disease virus on lymphoma cells .J Cancer Res Clinincol. 122 (7):409-41
Barry M, R C Bleackley. 2002. Cytotoxic T lymphocytes :all roads lead to death. Nat Rev Immunol,2(6):401-409
Bat liwalla F W, B A Bateman,D Serrano. 1998. A 15 year follow up of AJCC stage III malignanmelanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate andetermination of alterations in the CD8 T cell repertorie. Mol Med, 4(12):783-94
Bauer T M,L P Jiga,J J Chuang,M Randazzo,G Opelz,P Terness.2005.Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl Int,18:95-100
Baume D M, M J Robertson, H Levine, T J Manley, P W Schow, J Ritz. 1992 . Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. Eur J Immunol, 22 (1):1-6
Beard C W, R P Hanson. 1984. newcastle diease in disease of poultry. lowa state university press, 452-70
Beierle E A,L F Strande,M K Chen. 2002. VEGF upregulates Bcl-2 expression and is associated with decreased apoptosis in neuroblastoma cells. J Pediatr Surg,37(3):467-71
Bianh,P Fournier,R Moormann. 2005. Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus. Cancer Gene Ther, 12:295-303
Bianh,P Fournier,B Peeter. 2005. Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein . International Journal of Oncology, 27:377-84
Huang B ,P Y Pan, Q S Li,A I Sato,D E Levy,J Bromberg,C M Divino, S H Chen. 2006. Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing. Host Cancer Res, 66(2):1123-31.
Bottino, Cristina, S Sivori, L Moretta,A Moretta, R Biassoni. 2000. Identification and molecular characterization of a natural mutant of the p50.2/KIR2DS2 activating NK receptor that fails to mediate NK cel triggering.European Journal of Immunology,30(12):3569-74
Bowlin T L,P S Sunkara.Swainsonine.1988.an inhibitor of glycoprotein processing,enhances mitogen induced interleukin-2 production and receptor expression in human lymphocytes. Biochem BioPhys Res Commun,151:486-59
Breton P,A Asseffa,K Grzeorzewski.1990.Swainsonine modulation of protein kinase C activity in murine pevitoneal macrophages.Cancer Commun, 2(10):333-338
Brutkiewicz R R, V Sriram. 2002. Natural killer T (NKT) cells and their role in antitumor immunity. Crit Rev Oncol Hematol,41(3):287-98
Byrne S N,J Ahmed,G M Halliday. 2005. Ultraviolet B but not A radiation activates suppressor B cells in draining lymph nodes. Photochem Photobiol, 81(6):1366-70
Caligiuri M A, C Murray, M J Robertson, E Wang, K Cochran, C Cameron, P Schow, M E Ross, T R Klumpp, R J Soiffer. 1993. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest ,91(1):123-32
Caligiuri M A, A Zmuidzinas, T J Manley, H Levine, K A Smith, J Ritz. 1990. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors . J Exp Med, 171(5):1509-26
Carnaud C, D Lee, O Donnars, S H Psrk, A Beavis,Y Koezuka, A Bendelac. 1999. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol, 163(9):4647-50
Cassel W A, R Earl Garrett. 1965. Newcastle disease virus as antineoplastic agent.Cancer, 18(7):863-8
Cassel W A, D R Murray. 1988. Treatment of stageⅡmalignant melanoma Patients with a Newcastle disease virus oncolysate.Nat Immun Cell Growth Regul,7(5-6):351-2
Cassel W A,D R Murray.1992. A ten-year follow-uP on stage II malignant melanoma Patients treate postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacothe, 9(4):169-71
Catlett-Falcone R,T H Landowski,M M Oshiro,J Turkson, A Levitzki,R Savino, G Ciliberto ,L Moscinski ,J L Fernández-Luna ,G Nu?ez ,W S Dalton ,R Jove . 1999. Constitutive activation of stat3 signaling confers resistance to apoptosis in human U266 myeloma cells . Immunity, 10(1):105-15
Cesana G,G DeRaffele,S Cohen,D Moroziewicz, J Mitcham, J Stoutenburg, K Cheung,C Hesdorffer, S Kim-Schulze, H L Kaufman. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 (IL-2) for metastatic melanoma and renal cell carcinoma.J Clin Oncol 24(7):1169-77
Chang H C, Y C Huang, W C Huang. 2003. Antipro liferative and chemop reventive effects of adlay seed on lung cancer in vitro and in vivo . J Agric Food Chem , 51(12): 3656-60
Chao K H, M Y Wu, C D Chen, J H Yang, Y S Yang, H N Ho. 1999. The expression of killer cell inhibitory receptors on natural killer cells and activationstatus of CD4+ and CD8+ Tcells in the deciduas of normal and abnormal early pregnancies. Hum Immunol, 60(9):791-7
Chiang W C, C Y Cheng, M T Cihang, K T Chung. 2000. Effects of dehulled adlay on the cultue count of some microbiota and their metabolism in the gastrointestinal track of rats.J Agric Food Chem , 48(3): 829-32
Cologate S M, P R Dorling, C R Huxtable.1979.A spectroscopic inestigation of swainsonine:an α-mannosidase inhibitor isolated from swaisona canescons J Chem,32:2257-64
Colombo M P,S Piconese. 2007. Regulatory T-cell inhibition versus depletion:the right choice in cancer immunotherapy. Nat Rev Cancer, 7:880-7
Contini P, M Ghio, A Poggi, G Filaci, F Indiveri, S Ferrone, F Puppo. 2003. Soluble HLA-A,-B, -C and -G molecules induce apoptosis in T and NK CD8Tcells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol, 33(5):125-34
Coudert J D, J Zimmer, E Tomasello, M Cebecauer, E Vivier, W Held. 2005. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand2 expressing tumor cells. Blood, 106(5):1711-7
Csatary L K, S Eckhardt, I Bukosza,F Czegledi, C Fenyvesi, P Gergely, B Bodey, C M Csatary. 1993. Attenuated veterinary virus vaccine for the treatment of cancer.Cancer Detect Prev,l7(6):619-27
Csatary L K. 1971 .Viruses in the treat me nt of cancer .Lancet, 2 :825
Csatary L K,R W Moss, J Beuth. 1999. Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine(MTH - 68/H)Anticancer Res19 (1B):635-8
Cui J,T Shin,T Kawano,H Sato,E Kondo,I Toura,Y Kaneko,H Koseki,M Kanno, M Taniguchi.1997. Requirement for Va 14 NKT cells in IL-12-mediated rejection of tumors.Science,278:1623-6
Chang D H, K Osman, J Connolly, A Kukreja,J Krasovsky, M Pack, A Hutchinson, M Geller,N Liu, R Annable, J Shay, K Kirchhoff, N Nishi, Y Ando, K Hayashi, H Hassoun, R M Steinman, M V Dhodapkar. 2005. Sustained expansion of NKT cells and antigen-specific T cells after injection of a-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med, 201(9):1503-17
Daniluk J,M K Szerszen,L Borowska.1996. Tumor necrosis factor and interfere on production by peripheral blood leukocytes of patients with alcoholic cirrhosis. Arch Immunol Ther ExP Warsz,44(2-3):97-101
David H C, K Osman, J Connolly, A Kukreja, J Krasovsky, M Pack,A Hutchinson, M Geller, N Liu, RAnnable, J Shay, K Kirchhoff, N Nishi,Y Ando, K Hayashi, H Hassoun,M Ralph, Steinman,V Madhav, Dhodapkar. 2005. Sustained expansion of NKT cells and antigen-specific T cells after injection of a-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med, 201(9):1503-17
Del-Val M, D Lopez. 2002. Multiple proteases process viral antigens for presentation by MHC class I molecules to CD+8 Tlymphocytes. MolImmunol, 39(3-4):235-47
Dennis N. 2003. The new face of traditional Chinese medicine.S cience, 299(10):188-90
Dennis J W, K Koch, D Bechner. 1989. Inhibition of human HT29 colon carcinoma growth in vitro and in vivo by swainsonine and human imerferon-α2. Natl Cancer Inst,81:1028-30
Dennis J W,K Koch,Youscfis. 1990.Growth inhibition of human melanoma tumor xenogralts in athymic mice by soainsonine.Cancer Res,50:1867-9
Dennis J W,S L White,A M Freer. 1993. Carbonoyloxy analogs of the anti-metastatic drug swainsonine .Biochem Pharmacol,46(8):1459-66.
Di Santo J P,C A Vosshenrich. 2006. Bone marrow versus thymic pathways of natural killer cell devel opment . I mmunol Rev, 214(11):35- 46
Doubr ovina E S, M M Doubrovin, E Vider, R B Sisson, R J O'Reilly, B Dupont, Y M Vyas. 2003.
Evasion from NK cell immunity by MHC classⅠchain-related molecules expressing colon adenocarcinoma. J Immunol, 171(12):6891-9
Dunn G P,C M Koebel,R D Schreiber. Interferons, immunity and cancer immunoediting .2006. Nat Rev I mmunol, 6(11):836-48
Dunn G P, L J Old,R D Schreiber. 2004.The three Es of cancer immunoediting . Annu Rev Immunol, 22:329-60
DziadK S,C G Espinoa,H Kunz. 2003. Synthetic glycopeptides for the development of antitumor vaccines. Aust J Chem, 56:519-43
Eberl G,H R MacDonald. 1998. Rapid death and regeneration of NKT cells in anti-CD3epsilon- or IL-12-treated mice: a major role for bone marrow in NKT cell homeostasis. Immunity, 9(3):345-53
Ellis T M, R I Fisher. 1989. Functional heterogeneity of Leu 19“bright”+ and Leu19“dim”+ lymphokineactivated killer cells. J Immunol, 142(3):2949-54
Emoto M, S H Kaufmann. 2003. Liver NKT cells: an account of heterogeneity. Trends in Immunol,24(7):364-9
Ensor C M,F W Holtsberg,J S Bomalaski,Clark. 2002. Pegylated arginine deiminase (ADI-SS PEG20, 000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res, 62:5443-50
Farinha P,H Masoudi, B F Skinnider, K Shumansky, J J Spinelli, K Gill,R Klasa , N Voss, J M Connors, R D Gascoyne. 2005. Analysis ofmultiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma ( FL ). Blood,106(6):2169-74
Feng G, Q Z Kong, D S Huang, T Huang, H D Lu, Y Fei, J P Feng. 2004. Experimental Study on Inhibiting Angiogenesis in Mice S180 Sarcoma by Coix Lacryma-Jobi Injection . Cancer ResPrev Treat, 31(4):229-30
Florenes V A,N Bhattacharya,M R Bani,Y Ben-David,R S Kerbel,J M Slingerland. 1996. TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation betweenp21Cip1/ WAF1 and p27Kip1 in a human melanoma cell line lacking p15INK4B:evidence forcooperation betweenp21Cip1/ WAF1 and p27Kip1. Oncogene, 13(11):2447-57
Gajewski T F,Y Meng, C Blank, I Brown,A Kacha, J Kline, H Harlin. 2006. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev, 213(1):131-45
Gansuvd B, M Hagihara, Y Yu, H Inoue, Y Ueda, T Tsuchiya, A Masui, K Ando, Y Nakamura, N Munkhtuvshin. 2002. Human umbilical cord blood NK T cells kill tumors by multiple cytotoxic mechanisms. Hum. Immunol. 63(3):164-75
Gao W W, Y J Zhao,C N He. 2006. Survey of research on germp lasm resources of Coix L .in China. China Tradit Herb Drugs,37(2):293-5
Gazzaniga S,A I Bravo, A Guglielmotti, N van Rooijen, F Maschi, A Vecchi, A Mantovani, J Mordoh, R Wainstok. 2007. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft.J Invest Dermatol,127(8):2031-41
Giraudo E,M Inoue, D Hanahan. 2004. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest, 114(5):623-33
Glass B, L Uharek, M Zeis, H Loeffler, W M Ruchholtz, W Gassmann. 1996. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells. Br J Haematol, 93(2):412-20
Godfrey D I,K J Hammond,L D Poulton,M J Smyth, A G Baxter. 2000. NKT cells:facts,functions and fallacies.Immunol Today, 21(11):573-83
Gorelik L,R A Flavell. 2001. Immune-mediated eradication of tumors through the blockade of transfor ming growth factor-beta signaling in T cells. Nat Med, 7:1118– 22
Granerus M,W Engstrom. 2000. The effects of glycosylation inhibitors on proliferation of a wilms tumor cell line.Anticancer Res,20(2A):689-92
Groh V,R Rhinehart,R Habecker,M S Topp,S R Riddell,T Spies. 2001.Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol, 2(3):255-60
Groh V,A Steinle,S Bauer, T Spies. 1998. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science, 279 (5357):1737-40
Grzegorzewski K,S A Newton,Akiyamask. 1989. Induction of macroPhage tumoricidal activity,major histo comPatibility comPlex classⅡantigen(Iak) expression,and interleukin-1 Production by swainsonine.Cancer Commun,1:373-9
Guan C S, P Yi , Y J Liu, Z Chen. 2001.Clinical study on the effect of Coicis Semen injection on primary hepatic cancer.Ch J Integr Tradit Digest ,9(6):355-6
Guha-Thakurta N,J A Niajde.1997. Early induction of Proinflammatory Cytokinc and Type I interferon mRNAs Following Newcastle disease virus,PolyI [iI : rC ],or low dose LPS challenge og the mouse . J Interferon Cytokinc Res,17(4):197
Guiducci C,A P Vicari,S Sangaletti,G Trinchieri, M P Colombo. 2005. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res, 65(8):3437-46
Gumperz J E. 2004. CD1d-restricted“NKT”cells and myeloid IL-12 production: an immunological crossroads leading to promotion or suppression of effective anti-tumor immune Responses. J Leukoc Biol, 76(2):307-13
Hagemann T, S C Robinson,M Schulz, L Trümper,F R Balkwill,C Binder. 2004. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophagesis due to TNF-αdependent up-regulationof matrix metalloprotease. Carcinogenesis, 25(8):1543-9
Hasselblom S, U Hansson, M Sigurdardottir, H Nilsson-Ehle, B Ridell, P O Andersson. 2008. Expression of CD+68 tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. Pathol I nt, 58(8):529-32
Hass C,C Ertel ,S R Gerhard. 1998. Introduction of adhesive and costi mulatory immune functions into tumor cells by infection with Newcastle disease virus. Int J Oncol, 13 (6):1105-15
Haas C,V Schirrmacher. 1996. Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies. Cancer Immunol Immunother,43(3):190-94
Hasselblom S,U Hansson, M Sigurdardottir, H Nilsson-Ehle, B Ridell, P O Andersson. 2008. Expression of CD+68 tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. Pathol Int, 58(8):529-32
Hayakawa Y, N D Huntington, S L Nutt, S L Nutt, M J Smyth. 2006. Functional subsets of mouse natural killer cells. Immunol Rev, 214(1):47-55
Hayakawa Y, K Takeda, H Yagita, S Kakuta, Y Iwakura, L V Kaer, I Saiki, K Okumura. 2001. Critical contribution of IFN-a and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of α-galactosylceramide. Eur J Immunol,31(6):1720-7
Hayakawa Y, K Takeda, H Yagita, L Van Kaer, I Saiki, K Okumura. 2001. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J Immunol, 166(10):6012-8
Hermans I F, J D Silk, U Gileadi, M Salio, B Mathew, G Ritter, R Schmidt, A L Harris, L Old, V Cerundolo. 2003. NKT Cells Enhance CD4+ and CD8+ T Cell Rdsponses to Soluble Antigen In Vivo through Direct Interaction with Dendritic Cells.J Immunol,171(10):5140-7
HE Webb, C E Gordon Smith. 1970. Viruses in the treatment of cancer.Lancet, 295(7658):1206-9
Hidaky Y,T Kaneda,N Amino,Miyai, K. 1992. Chinese medicine,Coix seeds increase peripheral cytotoxic T and NK cell.Bio therapy,5(3):201-3
Hirano F,K Kaneko,H Tamura, H Dong, S D Wang, M Ichikawa, C Rietz, D B Flies, J SLau,G F Zhu,K Tamada, L P Chen. 2005. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeuticimmunity. Cancer Res, 65:1089-96
Holdenrieder S,P Stieber,A Peterfi,D Nagel, A Steinle, H R Salih. 2006. Soluble MICA in malignant diseases. Int J Cancer, 118(3):684-7
Hong S,D C Scherer,N Singh, S KMendiratta, I Serizawa, Y Koezuka,L Van Kaer. 1999. Lipid antigen presenta-tion in the immune system: lessons learned from CD1d knock-out mice. Immunol Rev,169:31-44
Houri J J,E Ogier-Denis,C Bauvy. 1992. swainsonine is a useful tool to monitor the N-linked glycoprotein as a function of the state of enterocytic differentiation of HT-29 cells.Eur J Biochem,205(3):1169-74
Hsu K C,C A Keever-Taylor,A Wilton,C Pinto, G Heller, K Arkun,R J O'Reilly, M M Horowitz,B Dupont. 2005. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood, 105(12):4878-84
Huang M O, T Liu, P Yuan. 2006. Observation of the therapeut effects of Kanglaite injection combined with chemotherap drug on advanced pulmonary carcinomas.Chin J Misdia , 6 (2):251-2
Huang W C, H C Chang. 2003. Methanolic extract osadlay seed suppresses COX-2 expression of human lung cancer cells via inhibition of gene transcription.J Agric FOOD Chemistry, 51(25):7333-7
Huang X,J Zhu,Y Yang. 2005. Protection against autoimmunity in nonlymphopenic hosts by CD4+CD25+regulatory T cells is antigen-specific and requires IL-10 and TGF-beta. J Immunol, 175(7):4283-91
HumPhries M J,K Mstsumoto,S L White. 1990. An assessment of effects of swainsonine on survival of mice injected with B16-F10 melanoma cells.Clin ExP Metastasis,8(1):89-102
Ibrahim R,H Frederickson,A Parr,Y Ward,J Moncur,S N Khleif. 2006. Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism. Cancer ,106 (5):1065-77
Iero M,R Valenti, VHuber,P Filipazzi,G Parmiani,S Fais,L Rivoltini. 2008. Tumour-released exosomes and their implications in cancer immunity.Cell Death Differ, 15(1):80-8
Ishikawa A, S Motohashi,E Ishikawa,H Fuchida,K Higashino,M Otsuji, T Iizasa, T Nakayama,M Taniguchi, T Fujisawa. 2005. A phase I study of a-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res, 11(5):1910-17
Ito Y, Y Nagai, K Maeno. 1982. Interferon production in miouse spleen cells and mouse fibroblasts(L cells) stimulated by various strains of Newcastle disease virus. J Gen virol, 62:349-52
Jackson M W,J S Roberts,S E Heckford, C Ricciardelli, J Stahl, D J Horsfall, W D Tilley. 2002. A potential autocrine role for vascular endothelial growth factor in prostate cancer.Cancer Res, 62:854-9
JargalsaikhanDagvadorj,YoshikazuNaiki,GantsetsegTumurkhuu,FerdausHassan,ShamimaIslam,NaokiKoide,IsamuMori,TomoakiYoshida,andTakashi Yokochi.2008. Interleukin-10 inhibits tumor necrosis factor-αproduction in lipopolysaccharide-stimulated RAW 264.7 cells through reduced MyD88 expression. Innate Immunity , 14(2):109-15
Jiang W Z, M L Xu ,R B Su. 2000. Evaluation of the accessory anti-tumor effect of adlay processing food .J Health Sci, 2(2):113-22
Jinushi M, T Takehara, T Tatsumi, N Hiramatsu, R Sakamori, S Yamaguchi, N Hayashi. 2005. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol, 43(6):1013-20
Jinushi M, T Takehara, T Tatsumi, T Kanto, T Miyagi, T Suzuki, Y Kanazawa, N Hiramatsu, N Hayashi. 2004. Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to the altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol, 173(10):6072-81
Joon Yun A,K A Bazar,P Y Lee. 2004. Tumors may modulate host immunity partly through hypoxia-induced sympathetic bias.Med Hypotheses, 63(2):352-6
Argilés J M, S Busquets, A Felipe,F J López-Soriano. 2005. Molecular mechanisms involved in muscle wasting in cancer and ageing:Cachexia revsus sarcopenia.Int J Biochem cell Biol,37(5):1048-104
Kaplan D H,V Shankaran,A S Dighe,E Stockert,M Aguet,L J Old,R D Schreiber. 1998.Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA, 95(13):7556-61.
Kawano T, J Q Cui,Y Koezuka, I Toura, Y Kaneko, H Sato, E Kondo, M Harada, H Koseki, T Nakayama, Y Tanaka, M Taniguchi. 1998. Natural killer-like nonspecific tumor cell lysis mediated by specific ligandactivated Vα14 NKT cells. Proc Natl Acad Sci USA, 95(10):5690-93
Kawano T, T Nakayama, N Kamada, Y Kaneko, M Harada, N Ogura, Y Akutsu, S Motohashi, T Iizasa, H Endo, T Fujisawa, H Shinkai, M Taniguchi. 1999. Antitumor cytotoxicity mediated by ligand-activatedhuman Vα24 NKT cells. Cancer Res, 59(20):5102-5
Kim J, C K Chang, T Hayden, F C Liu, J Benjamin, A J Hamerman, L L Lanier,S M Kang. 2007. The activating immunoreceptor NKG2D and its ligands are involved in allograft transplant rejection. J Immunol, 179(10):6416-20
Kim E S,M S Kim,A Moon. 2005. Trans forming growth factor ( TGF)-beta in conjunction with H-ras activation promotes malignant progression of MCF10A breast epithelial cells. Cytokine, 9(2):84-91
Kim J,C K Chang,T Hayden, F C Liu, J Benjamin, J A Hamerman, L L Lanier, S M Kang. 2007. The activating immunoreceptor NKG2D and its ligands are involved in allograft transplant rejection. J Immunol, 179(10):6416-20
Kim R, M Emi, K Tanabe. 2007. Cancer immuno editing from immune surveillance to immune escape. Immunology, 121(1):1-14
Kirchner H H,P Anton,J Atzpodien. 1995. Adjuvant treatment of locally advanced renal cancer with autologous virus- modified tumor vaccines. World J Urol, 13(3): 171-3
Kirn D H,F McCormick. 1996.Replicating viruses as selective cancer therapeutics. Mol Med Today,2(12):519-57
Kitamura H,K Iwakabe,T Yahata,S Nishimura, A Ohta, Y Ohmi, M Sato, K Takeda, K Okumura, LV Kaer, T Kawano, M Taniguchi, T Nishimura. 1999. The natural killer T(NKT)cell ligand a-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med,189(7): 1121-8
Kitamura H,K Iwakabe ,T Yahata ,S Nishimura ,A Ohta ,Y Ohmi ,M Sato , K Takeda ,K Okumura, L Van Kaer, T Kawano, M Taniguchi, T Nishimura. 1999. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.J Exp Med, 189(7):1121-8
Klein J L,J D Roberts,M D George. 1999. Swainsonine protects both murine and human haematopoietic from chemotherapeutic toxicity.Br J Cancer,80(1~2):87-95
Knowles H,R Leek,A L Harris. 2004. Macrophage infiltration and angiogenesis in human malignancy. Novartis Found Syrup, 256:189- 200
Konishi J, K Yamazaki, H Yokouchi, N Shinagawa, K Iwabuchi, M Nishimura. 2004. The characteristics of human NKT cells in lung cancer-CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients. Hum Immunol,65(11): 1377-88
Kono K,H Kawaida, A Takahashi. 2006. CD4+CD25 high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers.Cancer Immunol Immunother, 55(9);1064-71
Kruger-Krasagakes S, K Krasagakis, C Garbe, E Schmitt, C Hüls, T Blankenstein,T Diamantstein. 1994. Expression of interleukin 10 in human melanoma. Br J Cancer,70(6):1182-5
Kubota T, Y Haramaki, Y Oki, F Saito, A Kuroshima, M Numata. 1988. Antitumor activity of vinegar made from pearl barley grains.Nippon Nogeikagaku Kaishi, 62(1):23-8
Kuo C C,M C Shih,Y H Kuo,W C Chiang. 2001. Antagonism of free-radical-induced damage of adlay seed and its antiproliferative effect in human histolytic lymphoma U937 monocytic cells. J. Agric. Food Chem. 49(3):1564-70
Lanier L L, B C Corliss, J Wu, C Leong, J H Phillips. 1998. Immunoreceptor DAP12 bearing atyrosine-based activation motif is involved in activating NK cells. Nature, 391(2):703-7
Lavergne E, C Combadiere, M Iga, A Boissonnas, O Bonduelle, M Maho, P Debré, B Combadiere. 2004. Intratumoral CC chemokine ligand 5 over expression delays tumor growth and increases tumor cell infiltration . J Immunol, 173(6):3755-62
Leon K, K Garcia, J Carneiro, A Lage. 2007. How Regulatory CD25+CD4+T Cells Impinge on Tumor Immunobiology:The Differential Response of Tumors to Therapies.J Immunol,179(9):5659-68
Le Q T, G Shi, H Cao, D W Nelson, Y Wang, E Y Chen, S Zhao, C Kong, D Richardson, K J O'Byrne, A J Giaccia, A C Koong. 2005. Galectin-1:a link bet ween tumor hypoxia and tumor immune privilege. J Clin Oncol, 23(35):8932- 41
Lewis C E, J W Pollard. 2006. Distinct role of macrophages in different tumor microenvironments. Cancer Res, 66(2):605-12
Liang W,H Wang, T M Sun. 2003. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract.World J Gastr oenterol, 9 (3):495-8
Li D P. 2004. General survey and progress in clinical trals abroad over Kanglaite injection. CJIM,10(3):233-5
Li D P, J M Huang, W A Su. 1999. Chemical composition of Coixseed's fat. Tradit Chin Drug Res Clin Pharm, 10(2):99-101
Liebrich W,P Schlag,M Manasterki. 1991. In vitro and clinical characterization of Newcastle disease-virus modified autologous tumor cell vaccine for treatment of colorectal cancer Patients. Eur J Cancer ,27(6):703-10
Li F Y, H R Chen. 2000. Experimental study on traditional Chinese medicine Coix seed’s effect on effect enhancing, toxic reducing to chemo therapeutic drug cisp lat in and mitomycin . Acta Chin Med Pharm, 2(28):44-45
Li X, D F Ye,X Xie, H Z Chen,W G Lu. 2005. Proportion of CD4+CD25 regulatory T cell is increased in the patients with ovarian carcinoma. Cancer Invest, 23(5):399-403
Li Y. 1998. Analysis of long term results of treatment for advance nasopharyngeal carcinoma by Coicis Semen combined wItradi otherapy . Acta Med Sin , 11(1):10-11
Ljunggren H G, K Kirre. 1990. In search of the“missing self”: MHC molecules and NK cell recognition . Immunol Today,11(7):237-44
Lomniczi B. 1975. Thermostability of Newcastle disease virus strains of different virulence.Arch.virol.,47(3):249-55
Lorence R M, P A Rood, K W Kelley. 1988. Newcastle disease virus as an antineoplastic agent :induction of tumor necrosis factor-a and augmentation of its cytotoxicity. J Natl Cancer Inst,80(16):1305-12
Lorence R M, B B Katubig,K W Reichard. 1994. Complete regression of human fibrosarcoma xenogearts after local Newcastle disease virus therapy.Cancer Res, 54(23):6017-21
Lorence R M,K W Reichard,B B Katubig. 1994. Complete regression of human neuroblastom xenografts in athymic mice after local Newcastle disease virus therapy.J Natl Cancer Ins, 86(16):1228-33
Lorence R M,K W Reichard,C J Cascino. 1992. transformation of human fibroblastsenhances cytotoxicity and rePlication by New-castle disease virus(ND V).Proc Am Assoc Cancer Res, 33:398
Eva L,C A Savary,R S Freedman.1984. Mtural killer cell cytotoxic potential of patients with ovariancarcinoma and its modulation with virusmodified tumor cell extract.Cancer Immunol Imunother,17(2):124-9
Loza M J, L Zamai, L Azzoni, E Rosati, B Perussia. 2002. Expression of type 1 (interferon gamma) and type 2 (interleukin-13 , interleukin-5) cytokines at distinct stage of natural killer cell differentiation from progenitorcells. Blood, 99(4):1273-81
Lutsiak M E C, Y Tagaya, A J Adams, J Schlom, H Sabzevari. 2008. Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells. J Immunol 180:5871-81
Lu Y, Z M Zhang, R H Zhang. 1999. The study on anti neoplastic effect of Coix seed oil . Pharm Clin Chin Mater Med, 15 (6):21-23
Mailliard R B, Y I Son, R Redlinger, P T Coates, A Giermasz, P A Morel, W J Storkus, P Kalinski. 2003. Dendritic cells mediate NK cell help for Th1 and CTL responses: Two signal requirement for induction of NK cell helper function. J Immunol, 171(5):2366-73
Mallmann P,A M Eis-Hubinger,D Krebs. 1992. Lymphokine- activated tumor- infiltrating lymphocytes and autologous tumor vaccine in breast and ovarian cancer. Onkologie, 15(6):490-6
Mantovani A, A Sica, S Sozzani, P Allavenab, A Vecchib, M Locatia. 2004. The chemokine system in diverse forms of macr ophage activation and polarization .Trends Immunol, 25(12):677-86
Smyth M J,E M Wallace, S L Nutt, H Yagita, D I Godfrey, Y Hayakawa. 2005. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer.J Exp Med, 201(12):1973-85
Turk M J, J A Guevara-Pati?o, G A Rizzuto, M E Engelhorn, A N Houghton. 2004. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.J Exp Med,200(6):771-82
Matsumura Y,S N Byrne,D X Nghiem, Y Miyahara, S E Ullrich. 2006. A role for inflammatory mediators in the induction of immunoregulatory B cells. JI mmunol, 177(19):4810-17
Matsushita N,S A Pilon-Thomas,L M Martin,A I Riker. 2008. Comparative methodologies of regulatory T cell depletion in a murine melanoma model .J Immunol Methods,333(1-2):167-79
Meadows S K,M Eriksson,A Barber,C L Sentman. 2006. Human NK cell IFN-γproduction is regulated by endogenous TGF-β. Int Immunopharmacol, 6(6):1020-8
Medana I M, A Gallimore, A Oxenius,MarianneM A Martinic, H Wekerle, H Neumann. 2000. MHC class I-restricted killing of neurons by virus-specific CD+8 T lymphocytes is effected through the Fas/FasL ,but not the perforin pathway.Eur J Immunol,30(12):3623-33
Metelitsa L S, O V Naidenko, A Kant,H W Wu, M J Loza, B Perussia, M Kronenberg, R C Seeger. 2001. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol, 167(6):3114-22
Metelitsa L S, K I Weinberg, P D Emanuel, R C Seeger. 2003. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia, 17(6):1068-77
Miller A M, K Lundberg, V Ozenci, A H Banham, M Hellstr?m, L Egevad, PPisa. 2006. CD4+CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol, 177(10):7398-405
Mittal S, N A Marshall, L Duncan, D J Culligan, R N Barker,M A Vickers. 2008. Loca landsyste micinduction of CD4+CD25+regulatory T-cell population by non-Hodgkin lymphoma. Blood,111(11):5359-70
Miwa N, S Hayakawa, S Miyazaki, S Myojo, Y Sasaki, M Sakai, O Takikawa, S Saito. 2005. IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferon- gamma increase in normal pregnancy but decrease in spontaneous abortion .Mol Hum Reprod, 11(12):865-70
Mocikat R, H Braumuller, A Gumy, Oliver Egeter, Heike Ziegler, Uwe Reusch, Anja Bubeck, Jacques Louis, Reinhard Mailhammer, Gert Riethmüller, Ulrich Koszinowski, Martin R?cken. 2003. Natural killer cells activated by MHCⅠ(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity, 19(4):561-9
Mohla S,S White, K Grzegorzewski. 1990. Inhibition of growth of subcutaneous xenografts and metastasis of human breast carcinoma by swainsonine: modulation of tumor cell HLA class I antigens and host immune effector mechanisms.Anticancer Res, 10(6):1515-22
Monach P A, H Schreiber, D A Rowley. 1993. CD4+ and B lymphocytes in transplantation immunity. II Augmented rejection of tumor allografts by mice lacking B cells. Transplantation,55(6):1356-61
Moodycliffe A M, D Nghiem, G Clydesdale, S E Ullrich. 2000. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol,1(6):521-5
Moretta A, C Bottino, M Vitale, D Pende, C Cantoni, M C Mingari, R Biassoni, L Moretta.2001. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Ann Rev Immunol,9(4):197-223
Mortier E,T Woo, R Advincula, S Gozalo, A Ma. 2008. IL-15Rαchaperones IL-15 to stable dendritic cellmembrane complexes that activate NK cells via trans presentation. J Exp Med, 205(5):1213-25
Moss D M. 2003. The many faces of macrophage activation. Journal of leukocyte biology, 73(2):209-12 Munn D H,M D Sharma,J R Lee,K G Jhaver, T S Johnson, D B Keskin, B Marshall, P Chandler, S J
Antonia, R Burgess, C L Slingluff Jr, A L Mellor. 2002. Potential regulatory function of human dendritic cells expressing indoleamine2,3-dioxygenase.Science, 297(5588):1867-70.
Munn D H, M D Sharma, A L Mellor. 2004. Ligation of B7-1/B7-2 by human CD4+T-cells triggers indoleamine2,3-dioxygenase activity in dendritic cells. J Immunol, 172(7):4100-10
Nagaraj S,K Gupta,V Pisarev, L Kinarsky, S Sherman, L Kang, D L Herber, J Schneck, D I Gabrilovich. 2007. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med, 13:828-35
Nagler A, L L Lanier,S Cwirla, J H Phillips. 1989. Comparative studies of human FcRIII 2 positive and negative natural killer cells. J Immunol , 143(10):3183-91
Guha-Thakurta N,A Jeannine ,Majde. 1997. Early induction of Proinflammatory cytokine and type I interferon mRNAs following lcwcastle disease virus,POLY(rI:rc),or lowdose LPS challenge of the mouse. JInterferonCytokine-Ies,17(4):197-204
Natarajan K,N Dimasi,J Wang, R A Mariuzza, D H Margulies. 2002. St ructure and function of natural killer cell receptors: Multiple molecular solutions to self, non-self discrimination. Annu Rev Immunol, 20(4):853-85
Nicholl M, A Lodge, I Brown, S L Sugg, J Shilyansky. 2004. Restored immune response to an MHC-II-Restricted antigen in tumor-bearing hosts after elimination of regulatory T cells. J Pediatr Surg, 39(6):941-6
Nicol A,M Nieda,Y Koezuka, S Porcelli, K Suzuki, K Tadokoro, S Durrant, T Juji. 2000. Human invariant Vα24+ natural killer T cells activated byα-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells.Immunology, 99(2):229-34
Nicol A,M Nieda,Y Koezuka. 2000. Human invariant V alpha24+ natural killer T cells activated byalpha-galactosylceramide(KRN7000) have cytoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells, 99(2): 229-34 Mach N, G Dranoff. 2000. Cytokine-secreting tumor cell vaccines. Current Opinion in Immunology, 12(5):571-5
Nieda M, M Okai, A Tazbirkova, H Lin, A Yamaura, K Ide, R Abraham, T Juji, D J Macfarlane, A J Nicol. 2004. Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood,103(2):383-9
Nomura T, S Sakaguchi. 2005. Naturally arising CD25+CD4+ regulatory T cells in tumor immunity. Microbiol Immunol, 293:287-302
Numata M,A Ammamoto,A Moribayashi. 1994. Antitumor components isolated from the Chinese herbal medicine Coix lachrymal-jobi. Planta Med,60(4):356-59
Oh H, H Takagi, A Otani, S Koyama, S Kemmochi, A Uemura, Y Honda. 2002. Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): A mechanism contributing to VEGF-induced angiogenesis.Proc Natl Acad Sci, 99(1):383-8
Ohm J E,D P Carbone. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res, 23(2-3):263-72
Ohta A, E Gorelik, S J Prasad, F Ronchese,D Lukashev,M K Wong, X Huang, S Caldwell, K Liu, P Smith, J F Chen,E K Jackson,S Apasov, M Sitkovsky. 2006. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci, 103(35):13132-7
Oladipe O A, P M Furbert-Harris, I Laniyan. 2003. Enhanced Proliferation of functionally comPetent bone marrow cell in different strains of mice treated with swainsonine.Int ImmunoPharmacology,3(3):445-55
Olden K, P Breton,Grzegorzewski, Y Yasuda. 1991. The potential importance of swainsonine in therapy for cancer immunology.Pharmacol Ther,50(3):285-90.
Ormandy L A, T Hillemann, H Wedemeyer, M P Manns, T F Greten, F Korangy. 2005. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res, 65(6):2457-64
Ostrand-Rosenberg S. 2004. Animal models of tumor immunity, immunotherapy and cancer vaccines.Cancer Immunol Immunother,532:86-91
Ostrand-Rosenberg S, J G Michael,K C Virginia. 2000. STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma.J Immunol,165:6015-6019
Pardali K, A Moustakas. 2007. Actions of TGF-βas tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta,1775(1):21-62
Park J Y, M Z Yang, H S Jun. 2003. Effect of raw brown rice and Job’s tear supplemented diet on seem and hepatic lipid concentrations ,antioxidative system ,and immune function of rats.J Korean Soc Food Sci Nutr,32(2):197-206
Peng G, Z Guo, Y Kiniwa, V Kuishin, W Y Peng, T H Fu, Y W Daniel, Y C Li, Y. W Helen, R F Wang. 2005. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science, 309(5739):1380-4
Peng Y, Y Laouar, M O Li, E A Green, R A Flavell . 2004. TGF-βregulates in vivo expansion of Foxp3-expressing CD4+ CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci, 101(13):4572-7
Perez N, S Karumuthil-Melethil, R B Li. 2008. Preferential Costimulation by CD80 Results in IL-10-Dependent TGF-{beta} 1+-Adaptive Regulatory T Cell Generation. J Immunol, 180:6566-76
Phan G Q, J C Yang, R MSherry, P H wu, S L Topalian, D J Schwartzentruber, N P Restifo, L R Haworth, C A Seipp, L J Freezer, K E Morton, S A Mavroukakis, P H Duray, S M Steinberg, J P Allison, T A Davis, S A Rosenberg. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.Proc Natl Acad Sci , 100(14): 8372-7
Phuangsab A, R M Lorenc,K W Reichard. 2001. Newcastle disease virus therapy of human tumorxenografts: antitumor effects of local or systemic administration.cancer Lett,172(1):27-36
Poggi A, A M Massaro, S Negrini, P Contini, M R Zocchi. 2005. Tumor-induced apoptosis of human IL-2-activated NK cells: role of natural cytotoxicity receptors. J Immunol, 174(5): 2653-60
Pollard J W. 2004. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer, 4 (1):71-8
Polverini P J. 1987. Effect of macrophage depletionon growth and neovasculatization of hamsterbuccal pouch carcinomas. J Oral Pathol, 16(9):436-41
Powell L D, S W Whiteheart, G W Hart. 1987. Cell surface sialic acid influence tumor cell recognition in the mixed lymPhocyte reaction. J Immunol ,139(1):262
Power S, R Thiele, G Staehler. 1995. Tumor vaccination in renal cell carcinoma with and without interleukin--2(IL-2) as adjuvant.A clinical contribution to the development of effective active specific immunization. Urolog A, 34(3):215-20
Puangs A B A, R M Lorence, K W Reichard. 2001. Newcastle disease virus therapy of human tumor xenografts: Antitumor effects of local or systemic administration. Cancer Lett, 172:27-36
Qin Z, Richter G, T Schuler, I Sabrina, X T Cao, B Thomas. 1998. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med, 4:627-30
Reichard K W,Lorence R M,Cascino C J.1992. Newcastle disease virus selectively kills human tumor cells .J Surg Res, 52(5): 448-453
Reichard K W,R M Lorence,C J Cascino. 1992. N-myc oncogene enhances the sensitivity of neuroblastoma to killing by Newcastle disease virus .Surg Forum,43 :603
Reichard K W,R M Lorence, B B Katubig. 1993. Retinoic acid enhances killing of neu- roblastoma cells by Newcastle disease virus.J Pediatr Surg, 28(10):1221-6
Rodriguez P C, D G Quiceno, J Zabaleta. 2004. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen - s pecific T - cell responses. Cancer Res, 64: 5839-49
Rodriguez P C, A H Zea, K S Culotta, J Zabaleta , J B Ochoa , A C Ocho. 2002. Regulation of T cell receptor CD3zeta chain expression by L-arginine. J BiolChem, 277(24): 21123-9
Rooprai H K, A Kandanearatchi, S L Maidment. 2001. Evaluation of the effects of swainsonine, captopril, tangeretin and nobiletin on the biological behaviour of brain tumour cell in vitro. NeuroPothol APPl Neurobiol,27(1):29-39
Rouas-Freiss N, P Moreau, C Menier. 2007. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol, 17(6):413-21
Ruggeri L, M Capanni, E Urbani, P Katia, D S Warren, T Antonella, P Sabrina, R Daniela, F Francesco, A Franco, F M Massimo, V Andrea. 2002. Effectiveness of donor natural killer cell alloreactivit y in mismatched hematopoietic transplants. Science, 295(3):2097-100
RuggeriL, A Mancusi, M Capanni, U Elena, C Alessandra, A Teresa, S Martin, P Daniela, P Katia, B Emanuela, T Fabiana, B Erika,A Franco, F M Massimo, V Andrea. 2007. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value .Blood, 110 (1):433-40
Ryan A E, F Shanahan, J O'Connell, A M Houston. 2006. Fas ligand promotes tumor immune evasion of colon cancer in vivo. Cell Cycle, 5(3):246-9
Salceda S, T Tang, M Kmet, M Andrei, G Malavika, M Roberto, W H Liu, P Glenn, P Jackie. 2005. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res, 306(1):128-41
Savage H E, R D Rossen, E M Hessh. 1986. Antibody development to viral and allogenic tumorcell-associated antigens in patients with malignant melanoma and ovarium carcinoma treated with lysates of virus-infected tumor cells. Cancer Res,46(4 Pt2):2127-33
Schild H, P Von Hoegen, V Schirrmacher. 1989. Moddification of tumor cells b5 a low dose of Newcastle disease virus.Ⅱ.Augmented tumor specific 7 cell response as a result of CD4 and cd8 immune T cell cooperation cancer immunol immunother,28(1):22
Schreiber R D. 2005. Cancer vaccines 2004 opening address: themolecular and cellular basis of cancer immunosurveillance and immuno editing. Cancer Immun, 5( Suppl):1
Schlag P, M Manasterki, T Geneth. 1992. Active specific immunotherapy wit Newcastle disease virus modified autologous tumor cells following resection of live metastasis in colorectal cancer. First evaluation of clinical resPonse of Phase II trial .Cancer Immunol Immunother,35(5):325-30
Schreiber R D. 2004. Cancer vaccines opening address : themolecular and cellular basis of cancer immunosurveillance and immuno editing . Cancer Immun, 5 ( Supp l 1):1-8
Schunscher U, L Bai, V Umansky. 2000. Newcastle virus activates materophages for anti- tumor activity. Int JOncol, 16(2):363
Schwarz R E,D C Wojciechowicz,A I Picon.1999.Wheatgerm agglutinin-mediated toxicity in pancreatic cancer cell.Br.J Cancer,80(11):1754-62
Seki S, Y Habu, T Kawanura, T Kazuyoshi, D Hiroshi, O Takashi, H Hoshio. 2000. The liver as a crucial organin the first line of host defense: the roles of Kupffer cells, natural killer (NK) cells and NK1.1 Ag+ T cells in T helper 1 immune responses. Immunol Rev, 174(1):35-46
Serafini P, S C De, I Marigo, C Sara, D Luigi, G Giovanna, Z Paola, B Vincenzo. 2004. Derangement of immune responses by myeloid suppress or cells. Cancer I mmunol I mmunother, 53(2):64-72
Sessa C, D F Braud, A Perotti, B Jean, C Giuseppe, N Cristina, Z Flavia, G Luca, M Silvia, J José, D T Maurizio, Elisa Dall’ó, C Nicoletta. 2005. Trabectedin for women with ovarian carcinoma after treatmentwith platinum and taxanes fails. J Clin Oncol, 23(9):1867-74.
Shankaran V, H I keda, A T Bruce,J M White, E S Paul, J O Lloyd, D S Robert. 2001. IFN-γlymphocytes prevent primary tumour development and shape tumour immunogenicity . Nature, 410(6832)1107-11
Schirrmacher V, L Bai, V Umansky. 2000. Newcastle virus activates macrophages for anti-tumo activity. Int J Oncol, 16 (2):363-73
Schirrmacher V, A Griesbach, T Ahlertn. 2001. Antitumor effects of Newcastle Disease Virus in vivo:local versus systemic effect s.Int J Oncol,18(5):945-52
Schirrmacher V, C Haas, R Bonifer. 1997. Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface biding but not infection.Clin Cancer Res,3 (7):1135-48
Schirrm acher V,C Haas,R Bonifer. 1999. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory proper ties when using Newcastle disease virus.Gene Ther,6(1) : 63-73
Schirrmacher V, K Jurianz, C Roth. 1999. Tumor stimulator cell modification by infection with Newcastle disease virus :analysis of effects and mechanism in MLTC-CML culture. Int J Oncol,14(2):205-15
Shi F D, L V Kaer. 2006. Recip rocal regulation between natural killer cells and autoreactive T cells. Nat Rev Immunol, 6(10):751-60
Shih C K, W C Chiang, M L Kuo. 2004. Effects of adlay on azoxymethane-induced colon carcinogenesis in rats.Food Chem T oxicol, 42(8): 1339-47
Shi L,S Mai, S SIsrael, B Kylie, A T Joseph, H G Arnold. 1997. Granzyme B autonomously crosses the cell membrane and perforin initiates apoptosis and granzyme B nuclear localization.J Exp Med,185(5):855-66
Shi ZY, T X Li, Q P Wang. 2001. Applied study of Coicis Semen injection combined with chemoembo lization on midle and advanced stage liver cancer. Tumor, 21(3):233-4
Sica G L, I H Choi, G Zhu, T Koji, S D Wang, T Hideto, I C Andrei,B F Dallas, B Jürgen, L P Chen. 2003. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. I mmunity, 18(6):849-61
Smyth M J,N Y Crowe, Y Hayakawa, T Kazuyoshi, Y Hideo, I G Dale. 2002. NKT cells-conductors of tumor immunity. Curr Opin Immunol,14(2):165-71
Smyth M J, K Y Thia, S E Street, C Erika, A T Joseph, T Masaru, K Tetsu,B P Sonja, Y C Nadine, I G Dale. 2000. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med, 191(4):661-8
Smyth M J, M E Wallace, S L Nutt, Y Hideo, I G Dale, H Yoshihiro. 2005. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med, 201(12):1973-85
Sopit W, B Chanchai, K Supranee. 2001. Serum total sialiacid in cholangiocarcinoma patients : An ROC curve analysis . Clinical Biochemistry, 34 (7) : 537-41
Sredni B, M Weil, G Khomenok, L Ilana, T Seagal, Yael Mardor Zvi Ram , O Arie, K Amir, M Shalom, I C Yan, H Zvi. Rappaport ,F Ilya, A Michael, L L Dan, K Yona. 2004. Ammonium trichloro ( dioxoethylene-o,o’) tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res, 64 (5):1843-52
Steidl C, T Lee, S P Shah, F Pedro, G M Han, N Tarun, D Allen, S J Jones, I Javeed, D W Dennis, A B Martin, R Andreas, M H Hans-Konrad, M R Lisa, C Elias, D Jan, M Rita, R C James, R T Ray, E S Jaffe, LGeorg, M C Joseph, L M Staudt, W C Chan, R D Gascoyne. 2010. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med, 362(10):875-85
Steinbrink K, H Jonuleit, G Muller. 1999. Interleukin - 10 - treated human dendritic cells induce a melanoma - antigen - s pecificanergy in CD8 ( + ) T cells resulting in a failure to lyse tumor cells. Bl ood, 93:1634-42
Steock M, C Marland-Noske, M Manasterki. 1993. In vitro expansion and analysis of lymphocyte microcultures obtained from active specific immunization with autologou Newcastal disease virus modified tumor cells.Cancer Immunol Immunnother, 37(4):240-4
Takahashi T,K Haraguchi, S Chiba, Y Masaki, S Yoichi, H Hisamaru. 2003. Va 24+ natural killer T-cell responses against T-acute lymphoblastic leukaemia cells: implications for immunotherapy. Br J Haematol, 122(2): 231-9
Takahashi A, K Kono, J Itakura, H Amemiya, H Iizuka, H Fujii, Y Matsumoto. 2002. Correlation of vascular endothelial growth factor–c expression with tumor - infiltrating dendritic cells in gastric cancer. Oncol ogy, 62(2):121-7
Takeda K, Y Hayakawa, M Atsuta, H Seokmann, V K Luc, K Kimio, I Mamoru, Y Hideo, K Okumura. 2000. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. Int Immunol,12(6):909-14
Taniguchi M, M Harada , S Kojo , T Nakayama , H Wakao . 2003. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol,21:483-513
Tanimura A. 1961. Studies on the ant-itumor component in the seeds of Coix lachryma-jobi Lvar ma-yuen (Roman) Stapef II .Isolation and antitumor activity of coixenolide.Chem Pharm Bull,9(21):47-53
Tan YT, C Y Wei, T Li. 2001. Study on influence of immuno logic function of patients with primary hepatocarcinoma by totalext racts of Coix seed injection. Chin J Prev Treat, 8 (1):22-5
Terabe M, S Matsui, N T Nancy, H J Chen, C Watson, D D Donaldson, P C David, E P William,J A Berzofsky.2000. NKT cell-mediated repression of tumor immunosurveillanceby IL-13 and the IL-4R-STAT6 pathway.Nat Immunol,1(6):515-20
Terabe M,J M Park,J A Berzofsky. 2004. Role of IL-13 in regulation of anti-tumor immunity and tumor growth .Cancer Immunol,53(2):79-85
Terabe M, S Matsui, N Noben-Trauth, H J Chen, C Watson, D D Donaldson, D P Carbone, E P William,J A Berzofsky. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol, 1(6):515-20
Termeer C C, Schirrmacherv,E B Bmeker. 2000. Newcastle disease virus infection induces B7-1/B7-2-Independent T-cell activity in human melanoma cells.Cancer Gene Ther,7(2):316
Thorsten H, C R Stephen, S Matthia,LorenzT, B C FrancesR. 2004. Enhanced invasiveness of breast cancer cell lines upon cocultivation with macrophages is due to TNF-αdependent up-regulation of matrix metalloprotease. Carcinogenesis, 25(8):1543-9
Tokuda H, T Matsumoto , T Konoshima. 1990. Inhibitory effect on Epstein-Barr virus activation and anti-tumor promoting activities of Coix seed . Planta Medica, 56(6):653-54
Turk M J, J A Guevara-Patino, G A Rizzuto, E E Manuel, N H Alan. 2004. Concomitant tumor immunity to apoorly immunogenicmelanoma is prevented by regulatory T cells. J Exp Med, 200(6):771-82
Tyler J Curiel, C George, Z Linhua, A Xavier, P Cheng, M Peter,E H Melina, J R Conejo-Garcia, LZhang, B Matthew, Y Zhu, SH Wei, Ilona Kryczek, D Ben, G Alan, M Leann, L Andrew, L D Mary, K L Knutson, L Chen, W P Zou. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 10:942-9.
Tzadok-David Y,M Metzkin-Eizenberg,Z Zakay-Rones.1995. The effect of a mesogenic and lentogenic Newcastle disease virus strain on Burkitt lymphoma Daudi cells. J Cancer Res Clin Oncol, 121(3):169-74
Tzong-Tyng H, H Wang, E A Kingsley, G P Risbridger, P J Russell.2008. Molecular profiling of bladder cancer involvement of the TGF-beta pathway in bladder cancer progression . Cancer Lett , 265(1): 27-38
Ukita C, A Tanimura. 1961. Studies on the antitumor component in the seeds of Coix lachrymal-jobi variety ma-yuen . Isolation and anti-tumor activity of coixenolide.Chem Pharm Bull, 9(1):43-46
Umansky V, V A Shatrov, V Lehmann,S Volker . 1996. Induction of NO synthesis in macrophages by Newcastle disease virus is associated withactivation of nuclear factor-κB.Int Immunol, 8(4):491-8
Umer I, T Chaudhry, K Peter. 2006. Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-γand inhibit Tumor Growth . Cancer Research, 1(66): 10497- 10504
Varla Leftherioti M. 2004. Role of a KIRSP HLA2 C allorecognition-system in pregnancy. J Reprod Immunol, 62 (122) : 19-27
Voss S D, J Daley, J Ritz, J R Michael. 1998. Participation of the CD94 receptor complex in costimulation of human natural killer cells . J Immunol, 160(2):1618-26
Wang H, X Xie, WG Lu, D F Ye, H Z Chen, X Li, Q Cheng. 2004.Ovarian carcinoma cells inhibit T cell proliferation: suppression of IL-2 receptor beta and gamma expression and their JAK -STAT signaling pathway. Life Sci,74 (14):1739-49
Wang H Y, D A Lee,G Peng, Z Guo ,Y Li ,Y Kiniwa ,E M Shevach , R F Wang .2004. Tumor - specific human CD4 + regulatory T cells and their ligands : implications for i mmunotherapy. Immunity, 20(1):107-18
Wang L Y,N Azad,L Kongkaneramit, F Chen, Y Lu, B H Jiang, R Yon. 2008. The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation. J Immunol,180:3072-80
Wei C Y, D P Tang , K Tang. 2000. Experimental study on cyto toxicity of cell of primary hepatocarcinoma by to talext racts of Coix seed injection . Chin J Prev Treat, 7 (6) : 609-13
White S L, T Nagai, S K Akiyama. 1991. Swainsonine stimulation of the proliferation and colony forming activity of murine bon marrow.Cancer Commun,3:83-91.
Wittke F, R Hoffmann, J Buer. 1999. Interleukin 10 (IL-10):an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br J Cancer,79:1182 - 4
Wyckof J, W G Wang, E Y Lin, Y Wang, P Flona, E R Stanley, G Thomas, W Jeffrey, Pollard, S Jeffrey, C John. 2004. A paracrineloop between tumor cells and macromphages is required for tumor cellmigration in mammary tumors. Cancer Res, 64 (19): 7022– 9
Yang Y. 2003. Generation of major histocompatibility complex class I antigens. Microbes Infect,5(1):39-47
Yang Y, J Ochando,A Yopp, B S Jonathan, Y Z Ding. 2005. IL-6 plays a unique role ininitiating c-Maf expression during early stage of CD4 T cell activation. J I mmunol, 174(5):2720-9
Yang Y,J H Paik,Cho D,J A Cho,C W Kim. 2008. Resveratrol induces the suppression of tumor-derived CD4 +CD25+regulatory Tcells.Int Immunopharmacol ,8(4):542-7
Yang Z Z,A J Novak,M J Stenson. 2006. Intratumoral CD4 +CD25 +regulatory T -cell - mediated suppression of infiltrating CD4 +T -cells in B - cell non - Hodgkin lymphoma . Blood,107:3639- 46
Yewdell J W. 2003. Immunology hide and seek in the peptidome. Science, 301(5638):1334-5
Yoon S R,J W Chung,I Choi. 2007. Devel opment of natural killer cells from hematopoietic stem cells. Mol Cells, 24(1):1-8
Young N T, M Uhrberg. 2002. KIR expression shape cytotoxic repertoires :a development alprogram of survial. TRENDS in immunology, 23(2):71-5
Young J C,Y L Sook. 2005. Cytotojcity and Multidrug-Resistance Reversing Activity of Extracts from Gamma-Irradiated Coix lachrymal-jobii. Var ma-yuen Stapf Seed. J Korean Soc Food Sci Nutr,34(5):613-18
Zamai L, C Ponti,P Mirandola, G Giuliana, P Stefano, G Laura, C Lucio,V Marco. 2007. NK cells and cancer. J Immunol, 178(7):4011-16
Zang X, P Loke,J Kim,K Murphy,R Waitz,P J Allison.2003.B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad SciUSA,100(18):10388-92
Zea A H, P C Rodriguez, M B Atkins, C Hernandez, S Signoretti, J Zabaleta, D McDermott, D Quiceno, A Youmans, A O’Neil, J Mier, C A Ochoa.2005.Arginase - producing myeloid suppressor cells in renal cell carcinoma patients : amechanism of tumor evasion. Cancer Res, 65(15):3044-8
Zeis M, L Uharek, B Glass, J Steinmann, P Dreger, W Gassmann, N Schmitz. 1997. Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukaemia effect in mice. Br J Haematol, 96(4):757-61
Zeng J, P Fournier, V Schirrmader. 2002. Induction of interferon alpha and tumor necrosis factor-related apoptosis inducing ligand in human blood mononuclear cells by hemagglutinin2 neuraminidase but not F protein of Newcastle disease virus. Virology, 297 (1):19-30 .
Zhang J G, G Liu, J H Liu. 2003. Advanced pancreatic cance treated with Coicis Semen injection combined with 52 Fluorouracil and cisp lat in .Tumor (肿瘤) ,23(4) : 347
Zhang J M, J S Yang, Y J Zhao. 2002. Progress report in chemical constituents and pharmacological activities of Coix. Chin Pharm J, 37(1):82-111
Zhang J G, G S Xu. 2007. Suppression of FasL expression in tumor cells and preventing tumor necrosis factoreinduced apoptosis by adenovirus 14.7K is an effective escape mechanism for immune cells. Cancer Genetics and Cytogenetics ,179:112-7
Zha Y, C Blank, T F Gajewski. 2004. Negative regulation of T -cell function by PD– 1. Crit Rev I mmunol, 24:229-37
Zheng Y, Z Cai, S Wang, X Zhang, J Qian, S Hong, H Li, M Wang, J Yang, Q Yi. 2009. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug - induced apoptosis . Blood, 114 (17) : 3625-8
Zhou G, Z Lu, J D McCadden, H I Levitsky, A L Marson. 2004. Reciprocal changes in tumor antigenicity and antigen- specific T cell function during tumor progression. J Exp Med, 200(12):1581-92
Zhou S H, R Ou, L Huang,M Demetrius.2002.Critical role for perforinr,Fas/FasL2, and TNFR1-mediated cytotoxic pathways in down-regulation of antigen-specific T cells during persistent viralinfection. J Virol, 76(2):829-40
Zhu Q, J Y Liu, HW Xu, C M Yang, AZ Zhang, Y Cui, H B Wang. 2005. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system. World J Gast roenterol,11 (39):6125-9
Zorn U, I Dallmann, J Grosse. 1994. Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus .Cancer Biother, 9 (3):225-35
Zorn U, S Dnensing, F Langkopf. 1997. Active specific immunotherapy of renal cell carcinoma:cellular and humoral immune response. Cancer Biother RadioPharm, 12 (3):157-65
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |